Calvert Health System, Inc. and Subsidiaries

Consolidated Financial Statements and Supplementary Consolidating Information

Years Ended June 30, 2020 and 2019





Table of Contents

Indep	endent Auditors' Report
Finan	cial Statements:
(Consolidated Statements of Financial Position
(Consolidated Statements of Operations and Other Changes in Net Assets Without Donor Restrictions
(Consolidated Statements of Changes in Net Assets
(Consolidated Statements of Cash Flows
١	Notes to Consolidated Financial Statements
Supp	lementary Consolidating Information:
Calve	rtHealth Medical Center, Inc. and Subsidiary:
(Consolidating Statement of Financial Position
(Consolidating Statement of Operations and Other Changes in Net Assets Without Donor Restrictions
(Consolidating Statement of Cash Flows
Calve	rt Health System and Subsidiaries:
(Consolidating Statement of Financial Position
(Consolidating Statement of Operations and Other Changes in Net Assets Without Donor Restrictions
(Consolidating Statement of Cash Flows 43
Г	Description of Consolidating and Eliminating Entries 44



Independent Auditors' Report

Board of Directors Calvert Health System, Inc. Prince Frederick, Maryland

We have audited the accompanying consolidated financial statements of Calvert Health System, Inc. and Subsidiaries (the "System"), which comprise the consolidated statements of financial position as of June 30, 2020 and 2019, and the related consolidated statements of operations and other changes in net assets without donor restrictions, changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Calvert Health System, Inc. and Subsidiaries as of June 30, 2020 and 2019, and their consolidated results of their operations, changes in net assets and their cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.



Change in Accounting Principles

As described in Note 1 to the consolidated financial statements, during fiscal year 2020 the System retrospectively adopted Accounting Standards Update (ASU) 2016-18 Statement of Cash Flows (Topic 230), which requires that the statement of cash flows display the change in total cash and cash equivalents, including restricted cash and cash equivalents and ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230), which provides guidance on the presentation of certain cash receipt and payments in the statement of cash flows. Additionally, as described in Note 1 to the consolidated financial statements, the System adopted FASB ASU No. 2016-01, Financial Instruments – Overall (Subtopic 825-10), Recognition and Measurement of Financial Assets and Financial Liabilities, which requires the change in fair value in investments to be recognized in the performance indicator. Our opinion is not modified with respect to these matters.

Report on Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The 2020 consolidating schedules on pages 37 - 43 are presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial position, results of operations and changes in net assets without donor restrictions, and cash flows of the individual companies, and are not a required part of the consolidated financial statements. Such information and the other supplementary information on page 42 are the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The 2020 information has been subjected to the auditing procedures applied in the audit of the 2020 consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the 2020 information is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

Dixon Hughes Goodman LLP

Tysons, Virginia October 21, 2020

	2020	2019
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 27,706,649	\$ 23,343,813
Short-term investments	364,284	94,298
Patient accounts receivable, net	13,553,225	13,695,126
Inventories	3,078,253	2,532,744
Prepaid expenses and other assets	5,491,249	4,047,101
Assets limited as to use, current	999,928	994,928
Total current assets	51,193,588	44,708,010
Investments and other assets:		
Investments	93,957,800	95,916,402
Investments in affiliated enterprises	6,989,065	6,740,257
Assets limited as to use	6,315,797	7,660,934
Property and equipment, net	92,834,626	91,442,164
Insurance recoverable	5,352,219	4,339,175
Other assets	818,740	1,017,259
Total assets	\$ 257,461,835	\$ 251,824,201
LIABILITIES AND NET ASSETS		
Current liabilities:		
Accounts payable and accrued expenses	\$ 19,605,532	\$ 16,359,929
Current portion of long-term debt	2,488,777	2,417,949
Current portion of capital lease obligation	757,053	794,127
Advances from third party payors	2,936,279	3,263,944
Total current liabilities	25,787,641	22,835,949
Long-term debt, less current portion, net of unamortized		
debt issuance costs	53,822,197	56,249,231
Long-term capital lease obligation	866,624	1,623,677
Professional liability	6,342,128	4,980,724
Other long-term liabilities	1,307,469	1,362,745
Total liabilities	88,126,059	87,052,326
Net assets:		
Without donor restrictions:		
Unrestricted - general	162,315,682	156,612,291
Unrestricted - board designated	4,029,583	3,947,827
Unrestricted - noncontrolling interest in subsidiary	-	(37,501)
With donor restrictions	2,990,511	4,249,258
Total net assets	169,335,776	164,771,875
Total liabilities and net assets	\$ 257,461,835	\$ 251,824,201
See accompanying notes.		3

Calvert Health System, Inc. and Subsidiaries Consolidated Statements of Operations and Other Changes in Net Assets Without Donor Restrictions Years Ended June 30, 2020 and 2019

	2020	2019
Revenue:		
Net patient service revenue	\$ 150,366,613	\$ 151,905,227
Rental revenue	466,104	360,247
CARES Act provider relief funding	4,329,084	-
Other operating revenue	2,660,685	3,560,902
Total operating revenue	157,822,486	155,826,376
Expenses:		
Salaries and wages	68,514,634	69,087,949
Employee benefits	12,201,498	14,164,973
Supplies	28,001,716	28,721,698
Purchased services	7,016,201	6,805,379
Professional fees	8,186,497	7,924,056
Depreciation and amortization	12,027,045	11,661,942
Interest	2,304,517	1,858,758
Other	18,777,098	18,558,075
Total operating expenses	157,029,206	158,782,830
Income (loss) from operations	793,280	(2,956,454)
Nonoperating gains (losses):		
Investment income	3,138,530	2,532,453
Income from equity investments	1,388,998	1,267,831
Income tax expense	(304,000)	-
Net unrealized losses on investments (see Note 1 for		
details on the implementation of ASU 2016-01)	(977,599)	-
Loss on pension settlement		(13,581,965)
Total nonoperating gains (losses), net	3,245,929	(9,781,681)
Excess of revenue over expenses (expenses over revenue)	4,039,209	(12,738,135)
Net assets released from restrictions for capital acquisitions	1,883,439	144,853
Transfer of net assets	(100,000)	-
Other pension-related changes	-	14,621,628
Net unrealized gains on investments (see Note 1 for		
details on the implementation of ASU 2016-01)		2,210,896
Increase in net assets without donor restrictions	\$ 5,822,648	\$ 4,239,242

Calvert Health System, Inc and Subsidiaries Consolidated Statements of Changes in Net Assets Years Ended June 30, 2020 and 2019

	Without Donor Restrictions	Noncontrolling Interest	With Donor Restrictions	Total
Balance, June 30, 2018	\$ 156,373,254	\$ (89,879)	\$ 3,077,856	\$ 159,361,231
Excess of revenue over expenses (expenses over revenue)	(12,790,513)	52,378	-	(12,738,135)
Contributions	-	-	1,970,441	1,970,441
Net assets released from restrictions for capital acquisitions	144,853	-	(144,853)	-
Net assets released from restrictions to fund operating programs	-	-	(717,548)	(717,548)
Investment income on restricted net assets	-	-	42,944	42,944
Other pension-related changes	14,621,628	-	-	14,621,628
Net unrealized gains on investments (see Note 1 for details				
on the implementation of ASU 2016-01)	2,210,896		20,418	2,231,314
Increase in net assets	4,186,864	52,378	1,171,402	5,410,644
Balance, June 30, 2019	160,560,118	(37,501)	4,249,258	164,771,875
Excess of revenue over expenses	4,038,775	434	-	4,039,209
Contributions	-	-	677,969	677,969
Contributions (distributions) to noncontrolling interest in subsidiary	(37,067)	37,067	-	-
Net assets released from restrictions for capital acquisitions	1,883,439	-	(1,883,439)	-
Net assets released from restrictions to fund operating programs	-	-	(186,447)	(186,447)
Transfer of net assets	(100,000)	-	100,000	-
Investment income on restricted net assets			33,170	33,170
Increase (decrease) in net assets	5,785,147	37,501	(1,258,747)	4,563,901
Balance, June 30, 2020	\$ 166,345,265	\$ -	\$ 2,990,511	\$ 169,335,776

See accompanying notes. 5

Accounts payable, accrued expenses and other liabilities 4,295,809 (11,218,2 Net cash provided by operating activities 17,792,780 762,3 Cash flows from investing activities: Purchases of investments (41,029,545) (37,373,4 Sales of investments 42,348,130 62,439,4 Net increase in assets limited as to use (248,874) (56,2	0,644
Depreciation and amortization 12,027,045 11,661,6 Amortization of debt issuance costs 61,744 63,6 Donations restricted for capital acquisition (426,815) (867,2 Equity in earnings of affiliated enterprises (1,388,998) (1,267,6 Distributions from equity method investments 959,849 388,7 Realized net losses (gains) on investments (608,260) 118,6 Unrealized net (gains) losses on investments 977,599 (2,210,8 Loss on pension settlement - 13,581,9 Other pension-related changes - (14,621,6 Change in: - (14,621,6 Patient accounts receivable 141,901 (154,5 Inventories (545,509) (208,5 Prepaid expenses and other assets (2,265,486) 86,2 Accounts payable, accrued expenses and other liabilities 4,295,809 (11,218,2 Net cash provided by operating activities: 17,792,780 762,3 Cash flows from investing activities: - (41,029,545) (37,373,4 Sales of investments 42,348,130	
Amortization of debt issuance costs 61,744 63,9 Donations restricted for capital acquisition (426,815) (867,2 Equity in earnings of affiliated enterprises (1,388,998) (1,267,6 Distributions from equity method investments 959,849 388,7 Realized net losses (gains) on investments (608,260) 118,6 Unrealized net (gains) losses on investments 977,599 (2,210,8 Loss on pension settlement - 13,581,9 Other pension-related changes - (14,621,6 Change in: - (14,621,6 Patient accounts receivable 141,901 (154,5 Inventories (545,509) (208,5 Prepaid expenses and other assets (2,265,486) 86,2 Accounts payable, accrued expenses and other liabilities 4,295,809 (11,218,2 Net cash provided by operating activities: 17,792,780 762,3 Cash flows from investing activities: - (41,029,545) (37,373,4 Sales of investments 42,348,130 62,439,4 Net increase in assets limited as to use (248,874) (56,2	1 0/12
Donations restricted for capital acquisition (426,815) (867,2 Equity in earnings of affiliated enterprises (1,388,998) (1,267,6 Equity in earnings of affiliated enterprises (608,260) 118,6 Equity in earnings of affiliated enterprises (608,260) 118,6 Equity in earnings of affiliated enterprises (608,260) 118,6 Equity in earnings of affiliated enterprises (2,210,6 Equity in earnings of affiliated enterprises (2,265,486) 86,2 Equity in earnings of affiliated enterprises (2,265,486) 86,2 Equity in earnings of affiliated enterprises (2,265,486) 86,2 Equity in earnings of affiliated enterprises (2,265,486)	
Equity in earnings of affiliated enterprises (1,388,998) (1,267,6 Distributions from equity method investments 959,849 388,7 Realized net losses (gains) on investments (608,260) 118,6 (608,	•
Distributions from equity method investments 959,849 388,7 Realized net losses (gains) on investments (608,260) 118,6 Unrealized net (gains) losses on investments 977,599 (2,210,8 Loss on pension settlement - 13,581,9 Other pension-related changes - (14,621,6 Change in: - 141,901 (154,621,6 Patient accounts receivable 141,901 (154,509) (208,5 Inventories (545,509) (208,5 Prepaid expenses and other assets (2,265,486) 86,2 Accounts payable, accrued expenses and other liabilities 4,295,809 (11,218,2 Net cash provided by operating activities: 17,792,780 762,3 Cash flows from investing activities: 42,348,130 62,439,4 Sales of investments 42,348,130 62,439,4 Net increase in assets limited as to use (248,874) (56,2	
Realized net losses (gains) on investments (608,260) 118,6 Unrealized net (gains) losses on investments 977,599 (2,210,8 Loss on pension settlement - 13,581,9 Other pension-related changes - (14,621,6 Change in: - 141,901 (154,621,6 Patient accounts receivable 141,901 (154,509) (208,500) Inventories (545,509) (208,500)<	
Unrealized net (gains) losses on investments 977,599 (2,210,8 Loss on pension settlement Loss on pension settlement - 13,581,9 Control (14,621,60) Other pension-related changes - (14,621,60) Change in: - (14,901) (154,60) Patient accounts receivable 141,901 (154,60) (154,60) Inventories (545,509) (208,50) (208,50) Prepaid expenses and other assets (2,265,486) 86,200 Accounts payable, accrued expenses and other liabilities 4,295,809 (11,218,200) Net cash provided by operating activities 17,792,780 762,300 Cash flows from investing activities: 17,792,780 762,300 Purchases of investments (41,029,545) (37,373,400) Sales of investments 42,348,130 62,439,400 Net increase in assets limited as to use (248,874) (56,200)	
Loss on pension settlement - 13,581,5 Other pension-related changes - (14,621,6 Change in: - 141,901 (154,6 Patient accounts receivable 141,901 (154,6 (208,6 Inventories (545,509) (208,6 (2,265,486) 86,2 Accounts payable, accrued expenses and other liabilities 4,295,809 (11,218,2 Net cash provided by operating activities 17,792,780 762,3 Cash flows from investing activities: (41,029,545) (37,373,4 Purchases of investments (41,029,545) (37,373,4 Sales of investments 42,348,130 62,439,4 Net increase in assets limited as to use (248,874) (56,2	
Other pension-related changes - (14,621,60000000000000000000000000000000000	
Change in: Patient accounts receivable 141,901 (154,8 Inventories (545,509) (208,8 Prepaid expenses and other assets (2,265,486) 86,2 Accounts payable, accrued expenses and other liabilities 4,295,809 (11,218,2 Net cash provided by operating activities 17,792,780 762,3 Cash flows from investing activities: (41,029,545) (37,373,4 Purchases of investments (41,029,545) (37,373,4 Sales of investments 42,348,130 62,439,4 Net increase in assets limited as to use (248,874) (56,2	
Patient accounts receivable 141,901 (154,8 Inventories (545,509) (208,5 Prepaid expenses and other assets (2,265,486) 86,2 Accounts payable, accrued expenses and other liabilities 4,295,809 (11,218,2 Net cash provided by operating activities 17,792,780 762,3 Cash flows from investing activities: Purchases of investments (41,029,545) (37,373,4 Sales of investments 42,348,130 62,439,4 Net increase in assets limited as to use (248,874) (56,2	1,020)
Inventories Prepaid expenses and other assets Accounts payable, accrued expenses and other liabilities Net cash provided by operating activities Cash flows from investing activities: Purchases of investments Sales of investments Net increase in assets limited as to use (545,509) (208,5 (2265,486) 86,2 (11,218,2	/ 833)
Prepaid expenses and other assets Accounts payable, accrued expenses and other liabilities Net cash provided by operating activities Cash flows from investing activities: Purchases of investments Sales of investments Net increase in assets limited as to use (2,265,486) 86,2 17,792,780 (11,218,2 (11,2	
Accounts payable, accrued expenses and other liabilities 4,295,809 (11,218,2 Net cash provided by operating activities 17,792,780 762,3 Cash flows from investing activities: Purchases of investments (41,029,545) (37,373,4 Sales of investments 42,348,130 62,439,4 Net increase in assets limited as to use (248,874) (56,2	6,231
Net cash provided by operating activities 17,792,780 762,3 Cash flows from investing activities: Purchases of investments (41,029,545) (37,373,4 Sales of investments 42,348,130 62,439,4 Net increase in assets limited as to use (248,874) (56,2	•
Cash flows from investing activities: Purchases of investments Sales of investments Net increase in assets limited as to use (41,029,545) (37,373,4 42,348,130 62,439,4 (56,2)	0,201)
Purchases of investments (41,029,545) (37,373,4 Sales of investments 42,348,130 62,439,4 Net increase in assets limited as to use (248,874) (56,2	2,311
Purchases of investments (41,029,545) (37,373,4 Sales of investments 42,348,130 62,439,4 Net increase in assets limited as to use (248,874) (56,2	
Sales of investments 42,348,130 62,439,4 Net increase in assets limited as to use (248,874) (56,2	3.488)
Net increase in assets limited as to use (248,874) (56,2	
	6,253)
Distributions from equity method investments	6,228)
Purchases of property and equipment (13,419,508) (26,143,8	
Net cash used in investing activities (12,169,457) (2,140,3	0,313)
Cash flows from financing activities:	
Repayment of long-term debt (2,489,693) (2,251,8	1,821)
Payments on capital leases (794,127) (904,2	4,216)
Donations received restricted for capital acquisitions 426,815 867,2	7,237
Net cash used in financing activities (2,857,005) (2,288,8	8,800)
Net increase (decrease) in cash, cash equivalents,	
and restricted cash 2,766,318 (3,666,8	6,802)
Cash, cash equivalents, and restricted cash, beginning of year 27,456,182 31,122,9	2,984
Cash, cash equivalents and restricted cash, end of year \$\bigs_30,222,500 \\\$ 27,456,1	6,182

Notes to Consolidated Financial Statements

1. Organization and Nature of Business

Organization

Calvert Health System, Inc. and Subsidiaries (the "System"), a Maryland corporation formed on January 1, 2000, is the sole member of CalvertHealth Medical Center, Inc. (the "Hospital"), Calvert Health Ventures, Inc. (CHV), CalvertHealth Medical Group, LLC (CHMG), CMH Holding Company (Holding Co. I), and CMH II Holding Company (Holding Co. II).

The System and the Hospital are nonprofit, nonstock membership corporations formed under the laws of the State of Maryland, organized for charitable purposes and exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code (IRC).

The Hospital, located in Prince Frederick, Maryland, provides inpatient, outpatient and emergency care services for the residents of Calvert County and the surrounding areas. The Hospital was incorporated in Maryland in 1917. The Hospital has two wholly owned or controlled subsidiaries: CalvertHealth Foundation, Inc. (the Foundation) and Calvert Community Health, Inc. (CCH). The Foundation is a non-profit corporation that operates exclusively for the charitable purpose of supporting the Hospital. CCH is the Hospital's for-profit subsidiary organized to establish managed care contracts. CCH is currently inactive.

CHV is a for-profit corporation that owns and manages investments in certain health care related entities, including Calvert Surgery Center, LLC (CSC), an imaging center, and a physical therapy and sports rehabilitation center. CSC holds a 15% interest in Prince Frederick Surgery Center, LLC (PFSC).

CHMG is a limited liability company that employs physicians who provide health care services for the residents of Calvert County and the surrounding area.

Holding Co. I and Holding Co. II are nonprofit, nonstock membership corporations formed under the laws of the State of Maryland, organized for charitable purposes and exempt from federal income taxes under Section 501(c)(2) of the IRC. Holding Co. I owns a medical office building in Solomon's Island, Maryland. Holding Co. II owns interest in Calvert Medical Arts Center, LLC (CMAC).

Principles of consolidation

At June 30, 2020 and 2019, the System's consolidated financial statements include the accounts of the Hospital and its wholly owned or controlled subsidiaries, CHV, CHMG, Holding Co. I and Holding Co. II. All material intercompany transactions are eliminated.

2. Summary of Significant Accounting Policies

Basis of presentation

The consolidated financial statements are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America. Revenue are reported as increases in net assets without donor restrictions unless use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses are reported as increases or decreases in net assets without donor restrictions unless their use is restricted by explicit donor stipulation or by law. Contributions, including unconditional promises to give, with no donor-imposed restrictions are recognized in the period received as increases in net assets without donor restrictions. Contributions with donor-imposed restrictions are reported as increases in net assets with donor restrictions. Expirations of restrictions on net assets (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as reclassifications between the applicable classes of net assets. Donor restricted

contributions whose restrictions are met in the same reporting period are also initially reported as increases in net assets with donor restrictions and then reported as reclassifications between the applicable classes of net assets.

Income and realized net gains (losses) on investments are reported as follows:

- Increases (decreases) in net assets with donor restrictions if the terms of the gift or the System's
 interpretation of relevant state law require that they be added to the principal of a permanent net asset
 with donor restriction:
- Increases (decreases) in net assets with donor restrictions if the terms of the gift impose restrictions on the use of the income;
- Increases (decreases) in net assets without donor restrictions in all other cases.

Use of estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.

Cash and cash equivalents

Cash and cash equivalents consist primarily of highly liquid, unrestricted investments in U.S. Treasury bills, commercial paper, and other interest-bearing deposits with original maturities of three months or less. Primarily all of the System's cash and cash equivalents are maintained in one commercial bank, of which an aggregate maximum of \$250,000 is insured by the Federal Deposit Insurance Corporation (FDIC). The System's cash balance routinely exceeds the maximum amount insured by the FDIC.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying consolidated statements of financial position that sum to the total amounts shown in the accompanying consolidated statements of cash flows as of June 30:

	2020	2019
Cash and cash equivalents Assets whose use is limited	\$ 27,706,649	\$ 23,343,813
Internally designated for capital acquisition and scholarships Restricted under bond indenture agreement - held by trustee	1,515,923 999,928	3,117,441 994,928
Total cash, cash equivalents and restricted cash shown in consolidated statements of cash flows	<u>\$ 30,222,500</u>	<u>\$ 27,456,182</u>

Short-term investments

Short-term investments consist primarily of investments with maturities of less than one year from the date of purchase.

Inventories

Inventories consist primarily of drugs and medical supplies and are carried at the lower of cost or net realizable value, as determined principally by the first-in, first-out method.

Patient accounts receivable

Patient accounts receivable are reported at net realizable value. For receivables associated with services provided to patients who have third-party coverage, the System estimates net realizable value based on the estimated contractual reimbursement percentage, which in turn is based on current contract provisions and historical paid claims by payor. For self-pay accounts, including uninsured and patient responsibility accounts, the net realizable value is determined using historical collection experience, adjusted for estimated conversions of patient responsibility portions, expected recoveries and changes in trends to estimate implicit price concessions. Management continually reviews the estimated net realizable value of accounts receivable by monitoring cash collections, economic conditions and trends, changes in payor mix, changes in federal or state healthcare coverage and other matters.

Investments

Investments in fixed maturity and equity securities are recorded at fair value. Investment income, realized gains and losses and unrealized gains and losses on equity securities are reported in the accompanying consolidated statements of operations and other changes in net assets without donor restrictions unless restricted by the donor, in which case they are reported as an addition to, or deduction from, the appropriate net assets with donor restriction balance.

As of June 30, 2020 and 2019, \$1,617,753 and \$1,457,043 of the investments balance, respectively, are available to fund an executive severance and deferred compensation plan that has been established to provide benefits to the System's executive management team. The current portion amounts are included in accounts payable and accrued expenses and the noncurrent portion amounts are recorded as noncurrent liabilities in the accompanying consolidated statements of financial position as of June 30, 2020 and 2019.

Investments are exposed to certain risks such as interest rate, credit and overall market volatility. Due to the level of risk associated with certain investment securities, changes in the value of investment securities could occur in the near term, and these changes could materially differ from the amounts reported in the accompanying consolidated financial statements.

Investments in affiliated enterprises

Investments in affiliated, non-controlled enterprises are accounted for using the cost or equity method of accounting.

Assets limited as to use

Assets limited as to use primarily include assets held by trustees under indenture agreements and designated assets set aside by the Board of Directors for future capital improvements, over which the Board retains control and may, at its discretion, subsequently use for other purposes.

Property and equipment

Property and equipment acquisitions are recorded at cost, except for donated items, which are recorded at fair value at the date of donation. Renovations, alterations, and improvements that increase the useful lives or the functionality of the related assets are capitalized and subsequently depreciated over the remaining useful life of each class of depreciable assets. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. Useful lives range from 20 - 40 years for buildings, 5 - 10 years for equipment and 10 - 20 years for leasehold improvements. Interest cost incurred on borrowed funds during the construction period for capital assets is capitalized as a component of the cost of acquiring those assets.

Net assets

Net assets, revenue, gains, and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

Net Assets Without Donor Restrictions – net assets available for use in general operations and not subject to donor restrictions. All revenue without donor restrictions and donor restricted contributions whose restrictions are met in the same period in which they are received are accounted for in net assets without donor restrictions.

Net Assets With Donor Restrictions – net assets subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. All revenue with donor restrictions as to either timing or purpose of the related expenditures or required to be maintained in perpetuity as a source of investment income are accounted for in net assets with donor restrictions. When a donor restriction expires, that is when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions.

Other assets

Other assets consist of insurance recoverables and long-term other amounts receivable. Long-term other amounts receivable includes a promissory note that was entered into between the Hospital and PFSC on July 1, 2015 in the amount of \$1,800,000. The original terms and conditions of the promissory note were restated and amended on December 1, 2018 for a new principal amount of \$1,187,095, a fixed rate of 3.75%, four payments of interest only that commenced on January 1, 2019 and sixty monthly payments of principal and interest that commenced on May 1, 2019. The long-term portion of the outstanding principal amounted to \$738,740 and \$929,643 at June 30, 2020 and 2019, respectively.

Third-party advances

The Hospital receives advances from third-party payors to provide working capital for services rendered to the beneficiaries of such services. These advances are subject to periodic adjustment and are principally determined based on the timing difference between the provision of care and the anticipated payment date of the claim for service.

Consolidated statements of operations

For purposes of display, transactions deemed by management to be ongoing, major or central to the provision of health care services are reported as revenue or expenses, as applicable. Peripheral or incidental transactions are reported as non-operating gains or losses, as applicable.

Excess of revenue over expenses (expenses over revenue)

The consolidated statements of operations and other changes in net assets without donor restrictions report excess of revenue over expenses (expenses over revenue). Changes in net assets without donor restrictions that are excluded from this performance indicator, consistent with industry practice, include unrealized gains and losses on marketable investments (prior to adoption of ASU 2016-01), permanent transfers of assets to and from affiliates for other than goods and services, contributions of (and assets released from donor restrictions related to) long-lived assets.

Net patient service revenue

Net patient service revenue is recognized at the amount that reflects the consideration to which the System expects to be entitled in exchange for providing patient care. These amounts are due from patients, third party payors (including commercial and governmental programs), and others and includes variable consideration for retroactive revenue adjustments due to settlement of audits, reviews and investigations. Generally, the System bills the patients and third-party payors after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

The System charges are based on rates established by the State of Maryland Health Services Cost Review Commission (HSCRC); accordingly, revenue reflects actual charges to patients based on rates in effect during the period in which the services are rendered. Physician practice charges are based on either negotiated contracts with commercial payors, fee schedules with Medicare and Medicaid or standardized pricing for self-pay patients.

The System determines the transaction price based on standard charges for services provided, reduced by explicit price concessions provided to third party payors, financial assistance provided to uninsured or underinsured patients in accordance with the System's policies, and/or implicit price concessions provided to uninsured or underinsured patients. The System determines its estimates of explicit price concession based on contractual agreements, its financial assistance policies, and historical experience. The System determines its estimates of implicit price concessions based on its historical and expected collection experience. This estimate considers business and general economic conditions, trends in healthcare coverage and other collection indicators. Throughout the year, management assesses the adequacy of these implicit price concessions based upon its review of patient accounts receivable and collections to date. Other factors, such as account aging and payment cycles, are considered when estimating implicit price concessions. Certain amounts categorized as implicit price concessions under current accounting standards were previously categorized as provision for doubtful accounts.

Charity care and other community services

The Hospital provides care to patients regardless of their ability to pay. In identifying charity care, the Hospital assesses the patient's ability to pay, utilizing generally recognized poverty income levels for the community, and identifies certain cases where incurred charges are considered to be beyond the patient's ability to pay. Because the Hospital does not pursue collection of amounts determined to qualify as charity care, such amounts are not reported as a component of net patient service revenue or patient accounts receivable. The Hospital maintains records to identify and monitor the level of charity care it provides. These records represent the amount of charges forgone under its charity care policy. The charity policy of the Hospital provides free care to patients up to 200% of the federal poverty level and provides free care on a sliding scale between 200% and 300% of the federal poverty level.

The cost of charity care provided by the Hospital amounted to approximately \$2,087,000 and \$4,882,000 in 2020 and 2019, respectively. Rates charged by the Hospital for regulated services are determined based on an assessment of direct and indirect costs calculated pursuant to the methodology established by the HSCRC, and therefore the cost of charity services noted above for the Hospital is equivalent to its established rates for those services. For any charity services rendered by the System other than the regulated services of the Hospital, the cost of charity care is calculated by applying the estimated total cost-to-charge ratio for the non-Hospital services to the total amount of charges for services provided to patients benefitting from the charity care policies of the System's non-Hospital affiliates.

The Hospital receives monthly payments from the HSCRC or submits monthly payments with respect to an Uncompensated Care Fund (UCC) established for rate-regulated hospitals in Maryland. The UCC is intended to provide Maryland hospitals with funds to support the provision of uncompensated care at those hospitals as determined by the HSCRC. The Hospital contributed \$551,318 and \$559,044 for 2020 and 2019, respectively, to the UCC as required by the HSCRC. The Hospital did not receive any payments from the UCC in 2020 and 2019.

In addition to charity and uncompensated care, the System provides various health education programs, community screenings, classes, partnerships and neighborhood health centers, such as the following:

- Clinic eligibility workers that assist indigent patients to obtain healthcare and dental services,
- Health promotion programs and services, such as smoking cessation, blood pressure screenings and wellness programs, and
- Social services to assist patients in arranging for nonhospital healthcare services.

The HSCRC requires all Maryland hospitals to complete and submit a Community Benefit Report annually on December 15th for the preceding fiscal year. The Hospital's Community Benefit Report for the year ended June 30, 2019 and 2018 reported \$19,718,889 and \$18,375,823, respectively (unaudited), in community benefit services.

Other operating revenue

Other operating revenue of the System includes electronic health record income, cafeteria income, grant income, ground lease income and revenue from instructional classes and other operating programs.

CARES Act Provider Relief Funding

The System has received provider relief funding under the federal Coronavirus Aid, Relief and Economic Security (CARES) Act. These relief funds are considered non-exchange transactions subject to terms and conditions specified by the resource provider distributed by the Health Resources Service Administration (HRSA) section of the U.S. Department of Health and Human Services (HHS). These conditions create a restriction that such funds must be used to prevent, prepare or respond to the coronavirus (COVID 19), creating purpose restrictions in addition to conditions. This conditional grant revenue is recognized as other operating income to the extent conditions/restrictions for entitlement are met for coronavirus related expenses or lost revenues. The System reports conditional contributions for which the conditions and related restrictions are met in the same reporting period as net assets without donor restrictions. Such funds are subject to recoupment to the extent the conditions for entitlement are not met.

Tax-exempt status

The System is exempt from federal income tax under section 501(c)(3) of the IRC as a public charity. The System is entitled to rely on this determination as long as there are no substantial changes in its character, purposes, or methods of operation. Management has concluded that there have been no such changes and, therefore, the System's status as a public charity exempt from federal income taxation remains in effect.

The state in which the System operates also provides general exemption from state income taxation for organizations that are exempt from federal income taxation. However, the System is subject to both federal and state income taxation at corporate tax rates on its unrelated business income. Exemption from other state taxes, such as real and personal property taxes, is separately determined.

The System had no unrecognized tax benefits or such amounts were immaterial during the periods presented. For tax periods with respect to which no unrelated business income was recognized, no tax return was required.

Management has also considered the impact of unrelated business activities and has concluded that the System is not subject to unrelated business tax or any other taxes that could be imposed by the IRC or state taxing authorities. As such, no provision is made for income taxes and no asset or liability has been recognized for deferred taxes.

Subsequent events

In preparing these consolidated financial statements, the System has evaluated events and transactions for potential recognition or disclosure through October 21, 2020, the date the consolidated financial statements were issued.

New accounting pronouncements

Effective July 1, 2019, the System adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 2016-01, Financial Instruments – Overall (Subtopic 825-10), Recognition and Measurement of Financial Assets and Financial Liabilities. The primary impact of adopting ASU No. 2016-01 is the requirement to measure certain classes of investments at fair value with changes in fair value to be recognized in the performance indicator. It also eliminates the requirement to disclosure the fair value of long-term debt. The System has adopted the guidance in ASU No. 2016-01 at July 1, 2019 as reflected in the 2020 financial statement information and disclosures. As a result of the adoption of ASU No. 2016-01, net unrealized gains (losses) on investments that were previously excluded from the excess (deficiency) of revenues over expenses in the accompanying consolidated statements of operations are now included within the excess (deficiency) of revenues over expenses for the year ended June 30, 2020 as a component of investment income. Such net unrealized losses on investments reflected in nonoperating income (loss) for the fiscal year ended June 30, 2020 were \$(977,599). Prior to July 1, 2019, the net unrealized gains on investments of \$2,210,896 for the year ended June

30, 2019, have been presented consistent with the previous standards as a component of changes in net assets and excluded from the excess of revenues over expenses (expenses over revenue).

During fiscal year 2020, the System adopted FASB ASU 2016-18, *Statement of Cash Flows (Topic 230): Restricted Cash*, which requires amounts generally described as restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. This guidance is intended to improve the classification and presentation of changes in restricted cash on the statements of cash flows and will provide more consistent application of GAAP by reducing diversity in practice. The statement of cash flows for the year ended June 30, 2019 has been adjusted to reflect the retrospective application of the new accounting guidance.

During fiscal year 2020, the System also adopted FASB ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230), which provides guidance on the presentation of certain cash receipt and payments in the statement of cash flows. Upon adoption, the System made a policy election to classify distributions received from equity method investees under the cumulative earnings approach as cash inflows from operating activities unless the investor's cumulative distributions received less distributions received in prior periods that were determined to be returns of investment exceed cumulative equity in earnings recognized by the investor. When such an excess occurs, the current-period distribution up to this excess should be considered a return of investment and classified as cash inflows from investing activities. This standard has been adopted on a retrospective basis. The accompanying 2019 statement of cash flows have been updated to reflect the provisions of this standard which are included in the adjustments in the table below.

The following summary reflects the adjustments made to the accompanying statement of cash flows for the year ended June 30, 2019 as a result of the adoption of ASU 2016-18 and ASU 2016-15:

	As Previously Reported	<u>Adjustments</u>	As Adjusted
Net cash provided by operating activities	\$ 370,569	\$ 391,715	\$ 762,311
Net cash used in investing activities	\$ (2,527,364)	\$ 387,051	\$ (2,140,313)
Net decrease in financing activities	\$ (2,863,943)	\$ 575,143	\$ (2,288,800)
Net decrease in cash and cash equivalents	\$ (5,020,711)	\$ 1,353,909	\$ (3,666,802)
Cash and cash equivalents, beginning	\$ 28,364,524	\$ 2,758,460	\$ 31,122,984
Cash, cash equivalents and restricted cash, ending	\$ 23,343,813	\$ 4,112,369	\$ 27,456,182

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which was amended in June 2020 by ASU 2020-05, Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities. The amendments in ASU 2016-02 revised the accounting related to lessee accounting. Under the new guidance, the System will be required to recognize a lease liability and a right-of-use asset for all leases. ASU 2020-05 extended the effective for the System to July 1, 2020. The System adopted this standard effective July 1, 2020 using the modified retrospective transition approach for leases existing at, or entered into after, that date. The primary impact of adoption is a gross-up of right of use assets and lease liability for operating leases.

3. Net Patient Service Revenue

Management has determined that the System has an unconditional right to payment only subject to the passage of time for services provided to date based on just the need to either finalize billing for such services (i.e., charge lag) or to discharge the patient and bill for such services for patients who are still receiving inpatient care in the System's facilities at the statement of financial position date. Accordingly, the System accrues revenue and the related accounts receivable for services performed but not yet billed at the statement of financial position date for in-house patients. Thus, management has determined that System does not have any amounts that should be reflected separately as contract assets.

The System elected certain available practical expedients under FASB ASU 2014-09, *Revenue from Contracts with Customers (ASC 606)*, First, the System elected the practical expedient that allows nonrecognition of the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the System's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, the System does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the respective contracts. Additionally, the System has applied the practical expedient whereby all incremental customer contract acquisition costs are expensed as they are incurred, as the amortization period of the asset that the System otherwise would have recognized is one year or less in duration.

Estimated uncollectible amounts from patients are considered implicit price concessions (as defined in ASC 606) and, therefore, included in net patient service revenue. Such implicit price concessions reflected in net patient service revenue in the accompanying consolidated financial statements for the years ended June 30, 2020 and 2019 were \$2,892,679 and \$2,163,646, respectively.

The System routinely obtains assignments of (or is otherwise entitled to receive) patient benefits receivable under their health insurance programs, plans or policies (i.e., third-party payors). Third party payors include both government payors, which include Medicare, Medicaid, and management care organizations, and commercial insurance carriers. Agreements with third party payors typically provide for payments at amounts less than established charges. A summary of payment arrangements with third party payors, by service type, is as follows:

- Global budget revenue the Hospital has entered into agreements by which the third-party payors pay a
 percentage of approved HSCRC charges. A reduced percentage can be obtained if the payor advances a
 certain amount of working capital.
- Physician practice services CHMG has entered into agreements by which the third-party payors pay negotiated rates per procedures as defined in the term sheet of the agreements.
- Outpatient Rehabilitation Calvert Health Outpatient Rehabilitation has entered into agreements by which the third-party payor pay negotiated rates per procedures as defined in the term sheet of the agreements

Performance obligations are determined based on the nature of the services provided by the System. Revenue for performance obligations satisfied over time are recognized based on actual charges incurred in relation to total expected (or actual) charges. The System believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in our hospitals receiving services over multiple days. The System measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time are generally recognized when goods or services are provided and the System does not believe it is required to provide additional services to the patient. Generally, performance obligations satisfied at a point in time relate to patients receiving outpatient services in a single day. The System measures the performance obligation from the commencement of the outpatient service,

to the point when it is no longer required to provide services to that patient, which is generally the completion of the outpatient service.

All of the System's performance obligations generally relate to contracts with a duration of less than one year, therefore the System has elected to apply the optional exemptions provided under applicable standards and as a result is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

Generally, patients who are covered by third party payors are responsible for related deductibles and coinsurance, which vary in amount. The System also provides services to uninsured patients, and offers those uninsured or underinsured patients financial assistance, by either policy or law, from standard charges. The System estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charges by any explicit price concession, financial assistance, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustment to net patient service revenue in the period of the change. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense.

Consistent with the System's mission, care is provided to patients regardless of their ability to pay. Therefore, the System has determined it has provided implicit price concessions to uninsured patients and other patient balances (for example, copays and deductibles).

The System aggregates revenue from contracts with customers by type of service and payor source. Tables providing details of these factors are presented below.

Net patient service revenue disaggregated by service type for the year ended June 30, 2020 and 2019 are as follows:

	2020	2019
Global budget revenue Rehabilitation services Physician practice services Other health services	\$ 133,672,837 1,862,417 14,700,978 130,381	\$ 130,059,760 2,028,081 17,843,208 1,974,178
Total	<u>\$ 150,366,613</u>	<u>\$ 151,905,227</u>

Net patient service revenue disaggregated by payor for the years ended June 30, 2020 and 2019 are as follows:

	2020		2019
Medicare	\$ 74,596,628	-	64,997,219
Medicaid	20,783,174		20,381,383
Blue Cross	27,650,833		28,233,973
Commercial Managed Core	5,860,573		5,060,210
Managed Care Self-Pay	18,491,220 2,984,185		29,058,398 4,174,044
Sell-Fay	2,964,100	<u> </u>	4,174,044
Total	<u>\$ 150,366,613</u>	\$	151,905,227

4. Investments in Affiliated Enterprises

A summary of investments in affiliated enterprises as of and for the years ended June 30 follows:

	2020		2019	
	Investment	Income	Investment	Income
Equity:				
Calvert Medical Imaging Center	\$ 2,112,684	\$ 827,522	\$ 1,785,163	\$ 735,886
NRH/CPT Regional Rehab, LLC	-	-	-	243,107
Chesapeake-Potomac Healthcare			0.450.000	470 400
Alliance, LLC	3,622,493	169,525	3,452,968	179,463
ChoiceOne Urgent Care of Calvert	747 500	242 502	4 400 547	100.610
County, LLC	717,533	313,583	1,198,547	120,610
Prince Frederick Surgery Center, LLC	290,813	76,392	273,671	(11,325)
CoreLife Calvert Partnership, LLC	225,000	-	-	-
Cost:				
Freestate Healthcare Insurance				
Company, LTD	20,542	-	20,542	90
Maryland eCare, LLC		1,976	9,366	<u>-</u>
•				
	<u>\$ 6,989,065</u>	<u>\$ 1,388,998</u>	\$ 6,740,257	<u>\$ 1,267,831</u>

Because CHV's investment in Calvert Medical Imaging Center (CMIC) represents approximately 30% and 26% of the reported investment balance in affiliates as of June 30, 2020 and 2019, respectively, and the Hospital's investment in Chesapeake-Potomac Healthcare Alliance (the Alliance) represents approximately 52% and 51% of the reported investment balance in affiliates as of June 30, 2020 and 2019, respectively, and the Hospital's investment in ChoiceOne Urgent Care of Calvert County (ChoiceOne) represents approximately 10% and 18% as of June 30, 2020 and 2019, respectively, summarized financial information for CMIC, the Alliance and ChoiceOne is also presented as follows.

Calvert Medical Imaging Center

CMIC is a joint venture between CHV and American Radiology Services, Inc. that operates diagnostic imaging facilities. CHV maintains a 50% interest in CMIC.

Summarized unaudited financial information of CMIC as of and for the years ended June 30 is presented below:

	2020	2019
Total assets	<u>\$ 4,790,448</u>	\$ 4,591,182
Total liabilities Partners' capital	\$ 565,079 4,225,369	\$ 1,020,857 3,570,325
Total liabilities and partners' capital	<u>\$ 4,790,448</u>	\$ 4,591,182
Total revenue	<u>\$ 8,036,023</u>	\$ 8,051,883
Net income	<u>\$ 1,655,044</u>	\$ 1,473,367

NRH/CPT Regional Rehab, LLC

CHV invested in NRH/CPT Regional Rehab, LLC (NRH/CPT) for the purpose of providing comprehensive and coordinated physical therapy and rehabilitation services in St. Mary's and Charles counties. CHV maintained a 15% interest in NRH/CPT as of June 30, 2018. On April 30, 2019, CHV sold its entire membership interest in NRH/CPT.

Chesapeake-Potomac Healthcare Alliance, LLC

Chesapeake-Potomac Healthcare Alliance, LLC (The Alliance) is a joint venture in which the Hospital and two other hospitals have invested equally. It was created to provide certain healthcare services to the population of southern Maryland. The Alliance is a 60% owner of Chesapeake Potomac Regional Cancer Center, LLC (CPRCC), a limited liability company that owns and operates two outpatient radiation oncology centers. The other 40% of CPRCC is owned by Holy Cross Hospital of Silver Spring and Adventist Healthcare, Inc. The Alliance is also one of two members in Chesapeake-Potomac Home Health Agency, Inc., a Maryland nonstock corporation that was formed in 1995 for the purpose of providing home health care and other health care services to individuals in need of such services in Calvert, Charles and St. Mary's counties.

Summarized unaudited financial information of the Alliance as of and for the years ended June 30 is presented below:

	2020	2019
Total assets	<u>\$ 19,117,929</u>	\$ 16,742,390
Total liabilities Members' equity	\$ 3,829,427 <u>15,288,502</u>	\$ 2,199,754 14,542,636
Total liabilities and members' equity	<u>\$ 19,117,929</u>	\$ 16,742,390
Total revenue	<u>\$ 13,805,442</u>	\$ 14,829,915
Net income	<u>\$ 614,529</u>	<u>\$ 538,363</u>

ChoiceOne Urgent Care of Calvert County, LLC

ChoiceOnce is a joint venture which was formed in November 2018 to manage and operate the Dunkirk, Prince Frederick and Solomons Urgent Care locations. The Hospital maintained a 49% interest in this joint venture at June 30, 2019. In March 2020, there was a transition in ownership and the Hospital transferred a portion of its membership interests to the new management company. The Hospital now maintains a 25% interest in the joint venture at June 30, 2020.

Summarized unaudited financial information of ChoiceOne as of and for the years ended June 30 is presented below:

	2020	2019
Total assets	<u>\$ 1,356,644</u>	\$ 3,545,348
Total liabilities Partners' capital	\$ 429,707 926,937	\$ 1,099,727 2,445,621
Total liabilities and partners' capital	<u>\$ 1,356,644</u>	\$ 3,545,348
Total revenue	<u>\$ 3,848,970</u>	\$ 1,948,505
Net income	<u>\$ 640,230</u>	<u>\$ 246,142</u>

Prince Frederick Surgery Center, LLC

PFSC operates a surgical center in Prince Frederick Maryland. It was formed initially as a joint venture by five physicians in May 2009. On July 1, 2015, CSC acquired a 25% interest in PFSC. On December 1, 2018, CSC and the physician members agreed to an additional ownership interest that was issued to Surgical Center Development #3, LLC resulting in a new ownership structure where CSC now maintains a 15% interest in PFSC.

CoreLife Calvert Partnership, LLC

In March 2020, the System and CoreLife, Inc. created the CoreLife Calvert Partnership, LLC. The joint venture was created with the intent of opening and operating three weight management clinics in Calvert County and neighboring Charles County. CoreLife's innovative model addresses all facets of weight management as well as facilitates healthy lifestyles. This holistic approach aligns with the System's commitment to improving the health status of the community and its patients. The System maintains a 50% interest in the joint venture at June 30, 2020.

Freestate Healthcare Insurance Company, LTD

Freestate Healthcare Insurance Company, LTD is a captive insurance company formed in the Cayman Islands. It is owned by five Maryland hospitals. Freestate provides insurance coverage to its shareholders for professional liability and comprehensive general liability (see Note 10).

Maryland eCare, LLC

Maryland eCare, LLC is a joint venture formed by six Maryland hospitals to provide remote monitoring technology with clinical decision support and physician/nursing services for their use in intensive care units and other clinical areas within their respective hospitals. The Hospital maintained a 6.9% interest in this joint venture at June 30, 2019. Maryland eCare, LLC was dissolved effective June 11, 2020.

5. Investments

Investments, stated at market value, which approximates fair value, at June 30 include:

		2020		2019
Equity mutual funds Fixed maturity mutual funds Guaranteed investment account Corporate and municipal bonds Mortgage backed securities U.S. government issues Alternative investments	\$	39,457,378 13,803,097 350,921 19,105,539 1,394,003 10,959,089 9,252,057	\$	37,107,666 20,176,553 297,666 16,034,221 - 12,680,872 9,713,722
Less - short-term investments		94,322,084 364,284		96,010,700 94,298
Long-term investments	<u>\$</u>	93,957,800	\$	95,916,402
Assets limited as to use, stated at fair value, at June 30 include:				
Internally designated for capital acquisition and scholarships:		2020	_	2019
Cash and cash equivalents Net pledges receivable Equity mutual funds Exchange traded funds Fixed income mutual funds Less – current portion	\$ 	2,515,851 568,219 1,895,742 284,018 2,051,895 7,315,725 999,928	\$ 	4,112,369 516,040 1,759,701 325,567 1,942,185 8,655,862 994,928
	\$	<u>6,315,797</u>	\$	7,660,934

Management has \$100,000 on deposit to be used toward future charitable gift annuity arrangements. There were no outstanding charitable gift annuity obligations as of June 30, 2020.

Assets held by a trustee under the indenture agreement for debt service consist of the following funds at June 30:

		2020		2019
Held by trustee under indenture agreement:				
Cash and cash equivalents	<u>\$</u>	<u>999,928</u>	<u>\$</u>	994,928

The debt service fund was comprised of principal and interest funds held by a trustee in accordance with the Hospital's bond indentures.

Investment income and gains or losses for assets limited as to use, cash equivalents and other investments are comprised of the following for the years ended June 30:

	Year Ended June 30, 2020				
Investment Income	Without Donor Restrictions	With Donor Restrictions	Total		
Interest and dividends Realized gains Net unrealized loss on investments (see Note 1	\$ 2,821,155 608,260	\$ 29,944 4,538	\$ 2,851,099 612,798		
for implementation of ASU 2016-01) Investment expenses	(977,599) (290,885)	(1,312) 	(978,911) (290,885)		
	<u>\$ 2,160,931</u>	<u>\$ 33,170</u>	<u>\$ 2,194,101</u>		
		Ended June 30,	2019		
	<u>Year</u> Without Donor	Ended June 30, With Donor	2019		
Investment Income	Without		2019 Total		
Investment Income Interest and dividends Realized gains (losses) Investment expenses	Without Donor	With Donor			
Interest and dividends Realized gains (losses)	Without Donor Restrictions \$ 2,959,301 (118,695)	With Donor Restrictions \$ 32,764	Total \$ 2,992,065 (108,515)		

Current accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and establish a framework for measuring fair value, and establish a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date, as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Observable input other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

The following discussion describes the valuation methodologies used for financial assets measured at fair value. The techniques utilized in estimating the fair values are affected by the assumptions used, including discount rates, and estimates of the amount and timing of future cash flows. Care should be exercised in deriving conclusions about System's business, its value, or financial position based on the fair value information of financial assets presented below.

Fair value estimates are made at a specific point in time, based on available market information and judgments about the financial asset, including estimates of the timing, amount of expected future cash flows, and the credit standing of the issuer. In some cases, the fair value estimates cannot be substantiated by comparison to independent markets. In addition, the disclosed fair value may not be realized in the immediate settlement of the financial asset. Furthermore, the disclosed fair values do not reflect any premium or discount that could result from offering for sale at one time an entire holding of a particular financial asset. Potential taxes and other expenses that would be incurred in an actual sale or settlement are not reflected in the amounts disclosed.

Fair values for the System's fixed maturity securities are based on prices provided by its investment managers, who use a variety of pricing sources to determine market valuations. Each designate specific pricing services or indexes for each sector of the market based upon the provider's experience. The System's fixed maturity securities portfolio is highly liquid, which allows for a high percentage of the portfolio to be priced through pricing services.

Fair values of equity securities have been determined by the System from observable market quotations, when available. Private placement securities and other equity securities where a public quotation is not available are valued by using broker quotes.

The guaranteed investment account is valued at contract value, (which includes contributions made, adjusted for interest earned, withdrawals and administrative expenses) which approximates fair value.

The System's investments include investments in limited partnerships and other alternative investments, which are made in accordance with the System's investment policies. The limited partnerships acquire, hold, invest, manage, dispose of, and otherwise deal in and with securities of all kinds and descriptions. Publicly traded securities are generally valued by reference to closing market prices on one or more national securities exchange or generally accepted pricing services selected by the fund managers of the limited partnership. Securities not valued by such pricing services will be valued upon bid quotations obtained from independent dealers in the securities. The equity in earnings or losses from these investments is recorded as a component of investment income in the accompanying consolidated statements of operations and other changes in net assets without donor restrictions.

Although the various fund managers use their best judgment at estimating the fair value of the alternative investments, there are inherent limitations in any valuation technique. Therefore, the value is not necessarily indicative of the amount that could be realized in a current transaction. Future events will also affect the estimates of fair value, and the effect of such events on the estimates of the fair value could be material.

Calvert Health System, Inc. and Subsidiaries Notes to Consolidated Financial Statements

The following table presents the System's fair value hierarchy for assets measured at fair value on a recurring basis as of June 30, 2020:

	L	_evel 1	Lev	/el 2	Level 3	3	Total
Equity mutual funds:							
Foreign large growth	\$	74,870	\$	-	\$	-	\$ 74,870
Foreign large value	8	8,415,907		-		-	8,415,907
Foreign large blend		962,772		-		-	962,772
Large value		175,516		-		-	175,516
Large blend	2	4,865,438		-		-	24,865,438
Mid cap growth		16,506		-		-	16,506
Mid cap value		44,015		-		-	44,015
Mid cap blend		68,105		-		-	68,105
Small growth		17,917		-		-	17,917
Small value		28,691		-		-	28,691
Small blend	(6,382,943		-		-	6,382,943
World large stock		300,440		-		-	300,440
Fixed maturity mutual funds:							
Intermediate term bond	,	1,962,541		-		-	1,962,541
Intermediate core-plus bond		36,161		-		-	36,161
Inflation-protected bond		231,249		-		-	231,249
World bond		329,218		-		-	329,218
Tactical allocation	4	4,207,694		-		-	4,207,694
Ultrashort bond	,	9,088,129		-		-	9,088,129
Exchange traded funds		284,018					284,018
Corporate bonds	19	9,105,539		-		-	19,105,539
Mortgage backed securities	•	1,394,003		-		-	1,394,003
U.S. government issues							
(Maturity 1 - 10 years)	10	0,959,089		-		-	10,959,089
Guaranteed investment account		350,921					350,921
Total assets in fair value hierarch	/ <u>\$ 8</u> 9	<u>9,301,682</u>	<u>\$</u>	<u>-</u>	<u>\$</u>	<u> </u>	89,301,682
Cash and cash equivalents							2,515,851
Investments measured at NAV (a)							9,252,057
Investments at fair value							<u>\$101,069,590</u>

The following table presents the System's fair value hierarchy for assets measured at fair value on a recurring basis as of June 30, 2019:

	Level 1	Lev	rel 2	Lev	el 3	Total
Equity mutual funds:		·		·	<u>.</u>	
Foreign large growth	\$ 70,080	\$	-	\$	-	\$ 70,080
Foreign large value	6,872,200		-		-	6,872,200
Foreign large blend	1,459,957		-		-	1,459,957
Large growth	22,184		-		-	22,184
Large value	48,615		-		-	48,615
Large blend	23,965,701		-		-	23,965,701
Mid cap growth	33,424		-		-	33,424
Mid cap value	21,263		-		-	21,263
Mid cap blend	61,040		-		-	61,040
Small growth	14,555		-		-	14,555
Small value	14,519		-		-	14,519
Small blend	5,955,800		-		-	5,955,800
World large stock	328,029		-		-	328,029
Fixed maturity mutual funds:						
Intermediate term bond	1,774,058		-		-	1,774,058
Intermediate core-plus bond	50,711		-		-	50,711
Inflation-protected bond	204,444		-		-	204,444
World bond	337,255		-		-	337,255
Tactical allocation	3,887,964		-		-	3,887,964
Ultrashort bond	15,864,306		-		-	15,864,306
Exchange traded funds	325,567					325,567
Corporate bonds	16,034,221		-		-	16,034,221
U.S. government issues						
(Maturity 1 - 10 years)	12,680,872		-		-	12,680,872
Guaranteed investment account	297,666				<u>-</u>	297,666
Total assets in fair value hierarchy	\$ 90,324,431	\$	<u> </u>	\$	<u> </u>	90,324,431
Cash and cash equivalents						4,112,369
Investments measured at NAV (a)						9,713,722
Investments at fair value						<u>\$104,150,522</u>

⁽a) In accordance with current accounting standards, the alternative investments that were measured at net asset value per share (or its equivalent) have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the line items presented in the consolidated statements of financial position.

The accompanying consolidated financial statements of the System include total restricted and unrestricted hedge fund alternative investments as of June 30, 2020 and 2019 with the following characteristics:

The fund invests in the Master Fund, which is in underlying hedge funds. The underlying funds use a variety of investment strategies with distressed/structured products being the largest. The fund owned more than 50% of the Master Fund at December 31, 2020 and 2019. Liquidity restrictions include quarterly at net asset value with 95-days' notice. As of June 30, 2020 and 2019, the fund balance was to \$9,252,057 and \$9,713,722, respectively.

6. Pledges Receivable

During 2017, the Foundation commenced a capital campaign. Contributions from the campaign are being used to fund the Hospital's expansion project to build a three-story addition to its existing facility. At June 30, 2020, pledges receivables were \$633,193 less an allowance for uncollectible pledges of \$63,319 and a discount of \$1,655. The discount rate used was 0.29%. The pledges net receivable balance is included with Assets Limited as to Use and is reported as a non-current asset on the accompanying consolidated statements of financial position.

Anticipated collection of the pledges receivable at June 30, 2020 is as follows:

2021	\$ 284,755
2022	183,658
2023	104,979
2024	 59,801
	633,193
Less - allowance for uncollectible accounts	63,319
Less - discount	 1,655
Total	\$ 568,219

7. Net Assets with Donor Restrictions

	 2020	 2019
Subject to expenditure for specified purposes: Purchases of building and equipment Health education Health care services Gift annuity reserve	\$ 1,460,164 694,617 260,420 100,000	\$ 2,694,421 706,075 373,452
Total subject to expenditure for specified purposes	 2,515,201	 3,773,948
Investments to be held in perpetuity, the income from which is expendable to support health education	 475 <u>,310</u>	 475,310
Total net assets with donor restrictions	\$ 2,990,511	\$ 4,249,258

8. Property and Equipment

A summary of property and equipment at June 30 follows:

	2020	2019
Land improvements Buildings Building improvements Fixed equipment Movable equipment	\$ 5,503,943 45,591,068 51,078,928 17,084,817 76,884,996	\$ 2,632,705 34,706,544 44,495,369 4,826,334 70,987,736
Less - accumulated depreciation and amortization	196,143,752 114,002,207	157,648,688 102,448,870
Land Construction in progress	82,141,545 6,016,980 <u>4,676,102</u>	55,199,818 6,016,980 30,225,366
Property and equipment, net	<u>\$ 92,834,627</u>	<u>\$ 91,442,164</u>

In September 2017, the Hospital held a ground-breaking ceremony for a new capital expenditures project related to the building of a three-story addition to the existing facility. The two main objectives of the project are to expand the number of private patient rooms in the Hospital and to create an 18-room dedicated observation unit. The total project cost was approved for \$51,583,000 and is being funded internally from operating cash and investments.

In September 2017, the Hospital entered into an agreement for building contractor services for the three-story addition, renovation of second and third floor nursing units and other interior renovations. Under the agreement, the Hospital is obligated to pay the building contractor a contract sum of \$28,553,000. As of June 30, 2020, approximately \$28,375,000 has been paid to the contractor. If the Hospital were to terminate the agreement, it would be liable for payment of materials and supplies committed to that date along with reasonable overhead and profit. The project is expected to conclude in fiscal year 2021.

Interest cost incurred on borrowed funds during the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets. Interest capitalized for the years ended June 30, 2020 and 2019 amounted to \$281,925 and \$753,584, respectively.

In April 2020, the Hospital entered into a construction contract for a capital expenditure project of \$3.4 million. Subsequent to the balance sheet date, the Hospital entered into two additional contracts for capital expenditure projects of \$2.7 million. If the Hospital were to terminate the agreements, it would be liable for payment of materials and supplies committed to that date along with reasonable overhead and profit. The projects are expected to be completed by March 2021.

Depreciation expense for the years ended June 30, 2020 and 2019 amounted to \$12,027,045 and \$11,661,942, respectively.

9. Long-Term Debt

Long-term debt consists of the following as of June 30:

		2020	 2019
Maryland Health and Higher Educational Facilities Authority Revenue Bonds (2012 Revenue Bonds); maturing in varying amounts from September 1, 2012 to June 1, 2027; interest due monthly at a fixed rate of 3.16% per annum until July 24, 2022 at which time the interest rate shall be adjusted.	\$	10,001,377	\$ 11,284,839
Maryland Health and Higher Educational Facilities Authority Revenue Bonds (2013 Revenue Bonds); maturing in varying amounts from July 1, 2014 to July 1, 2038; interest due semi-annually at rates ranging from 3.0% to 5.18%; (5.0% and 4.0% at June 30 2020 and 2019, respectively).		29,940,000	30,190,000
Maryland Health and Higher Educational Facilities Authority Revenue Bonds (2015 Revenue Bonds); maturing in varying amounts from October 1, 2015 to September 1, 2035; interest due monthly at a fixed rate of 3.282% per annum.		16,987,599	 17,872,086
Less - current portion		56,928,976 2,488,777	 59,346,925 2,417,949
Less - unamortized debt issuance costs Less - unamortized original issue discount		54,440,199 541,646 76,356	 56,928,976 597,366 82,379
	<u>\$</u>	53,822,197	\$ 56,249,231

Series 2012 Revenue Bonds

The 2012 Revenue Bonds were issued by the Maryland Health and Higher Education Facilities Authority (Authority) on July 1, 2012 for the purpose of refunding the 1998 Revenue Bonds. The master loan agreement for the 1998 Revenue Bonds remained substantially unchanged.

The Obligated Group for the 2012 Revenue Bonds is composed of the Hospital and the System. The financing was completed through SunTrust Bank and is a tax-exempt issuance. Terms of the financing agreement included an initial fixed rate of 2.6% per annum until July 24, 2022, at which time the interest rate shall be adjusted and the 2012 Revenue Bonds are subject to mandatory purchase unless SunTrust Bank agrees to extend such period, the Obligated Group obtains another purchaser, or the Authority, at the request of the Obligated Group, converts the interest mode applicable to the 2012 Revenue Bonds to another interest mode for which a purchaser can be found. Terms of the financing agreement also included a requirement that the interest rate be increased as a result of a decrease in the maximum federal corporate income tax rate. With the passage of The Tax Cuts and Jobs Act of 2017, effective January 1, 2018 the maximum federal corporate income tax rate decreased from 35% to 21% resulting in an increase of the fixed rate from 2.6% to 3.16%. The 2012 Revenue Bonds mature on June 1, 2027. The 2012 Revenue Bonds require the Obligated Group to maintain a certain debt service coverage ratio.

Series 2013 Revenue Bonds

The 2013 Revenue Bonds were issued by the Authority on August 7, 2013 for the purpose of refunding the 2004 Revenue Bonds.

The Obligated Group for the 2013 Revenue Bonds is composed of the Hospital and the System. As security for the performance of its obligations under the related Loan Agreement, the Obligated Group members have granted a security interest in its receipts, revenue, rental income and other amounts received by or on behalf of any Obligated Group member to the Authority. The Obligated Group is not required to maintain a debt service reserve fund. The Series 2013 Revenue Bonds also place limits on the incurrence of additional borrowings and require the Obligated Group to maintain a certain debt service coverage ratio. Series 2013 bonds maturing on or after July 1, 2024 are subject to redemption prior to maturity beginning on July 1, 2023 at the option of the Authority upon the direction of the Hospital.

Series 2015 Revenue Bonds

The 2015 Revenue Bonds were issued by the Authority on September 10, 2015 for the purpose of financing the expansion and renovation of the radiology department at the Hospital, the acquisition and installation of a new information technology system, the acquisition of a parcel of land and the acquisition and installation of certain fixtures, equipment and machinery for the Hospital.

The Obligated Group for the 2015 Revenue Bonds is composed of the Hospital and the System. The financing was completed through The Columbia Bank and is a tax-exempt issuance. Terms of the financing agreement include a fixed rate of 2.7% for ten years with an amortization schedule of twenty years. Terms of the financing agreement also included a requirement that the interest rate be increased as a result of a decrease in the maximum federal corporate income tax rate. With the passage of The Tax Cuts and Jobs Act of 2017 the maximum federal corporate income tax rate decreased from 35% to 21% resulting in an increase of the fixed rate from 2.7% to 3.3% effective January 1, 2019. The Obligated Group is not required to main debt service reserve fund.

Principal payments due under all debt instruments as of June 30, 2020 are as follows:

2021	\$	2,488,777
2022		2,559,191
2023		2,636,243
2024		2,708,594
2025		2,785,403
Thereafter	_	43,750,768
Total	\$	56.928.976

Interest paid on indebtedness by the System was \$2,405,576 and \$2,343,750 in 2020 and 2019, respectively.

10. Employee Retirement Plans

The Hospital's retirement program consists of a qualified defined benefit plan (DB plan) and a defined contribution plan (DC plan). The DB plan was terminated and plan assets were distributed in November 2018.

Defined Benefit Plan

The Hospital had a qualified non-contributory DB plan covering employees who were employed by the Hospital prior to January 1, 2008. Effective January 1, 2008, employees hired or rehired were not eligible to participate in the DB plan. The Hospital instituted a "hard freeze" on December 31, 2016. The DB plan remained operational and continued to pay distributions to Hospital employees as they separated or requested a distribution during 2018 until the DB plan was terminated; however, no additional benefits were accrued. Effective September 24, 2017 a plan termination was approved by the CHS Board of Directors and accordingly, the plan was amended and restated to include such termination. Substantial settlement related to the termination began with cash distributions in October 2018. An annuity was purchased for participants in a pay status and for participants who elected to defer benefits until their retirement. As a result, a settlement charge of approximately

Calvert Health System, Inc. and Subsidiaries Notes to Consolidated Financial Statements

\$13,582,000 was recorded as a component of net benefit cost within other non-operating gains (losses) in the accompanying consolidated statements of operations for the year ended June 30, 2019.

The Hospital used a June 30 measurement date for its DB plan in 2019.

The following table sets forth the changes in the projected benefit obligation at June 30, 2019:

Benefit obligation at beginning of year	\$ 40,437,739
Interest cost	548,345
Actuarial gain	(1,321,201)
Benefits paid	 (39,664,883)
Benefit obligation at end of year	\$

The following table sets forth the changes in the plan assets at June 30, 2019:

Fair value of plan assets at beginning of year Actual return on plan assets Employer contributions Actual benefits paid	\$ 29,207,520 (376,337) 10,833,700 (39,664,883)
Fair value of plan assets at end of year	\$ <u>-</u>

In accordance with current standards, the Hospital recognized the full extent of the underfunded (a liability) status of the DB plan as a current liability in the accompanying 2019 consolidated financial statements, and the underfunded status is measured as the difference between the fair value of the DB plan assets and the projected benefit obligation. The plan was fully funded as of November 16, 2018.

Net periodic pension cost for the year ended June 30, 2019 include the following components:

Interest cost Expected return on plan assets Recognized net actuarial loss	\$ 548,345 (296,401) 391,200
Preliminary periodic benefit cost Settlement loss	643,144 <u>13,581,965</u>
	<u>\$ 14,225,109</u>

The following table sets forth the weighted average assumptions used to determine net periodic benefit costs for the years ended June 30, 2019:

Discount rate	4.36%
Expected return on plan assets	2.60%

Defined Contribution Plan

The Hospital has a DC plan for employees hired or rehired after January 1, 2008. Effective January 1, 2017, participants previously in the DB plan became eligible for the DC plan. Employees credited with 1,000 hours of service in a plan year receive an employer annual contribution of 2.5% of their annual wages. On a pay period basis, the Hospital provides a 50% matching contribution not to exceed 2% of plan compensation to all participating employees. If a participant has 10 years of service and is 55 years of age, the Hospital will provide a 50% matching contribution not to exceed 3% of plan compensation.

The employer total annual contributions to the DC plan were \$1,465,554 and \$1,502,412 during the years ended June 30, 2020 and 2019, respectively.

11. Malpractice Insurance

Prior to March 1, 2005, the Hospital maintained a professional liability insurance policy on a claims-made basis. Under this insurance policy, the Hospital was insured for individual claims up to \$1,000,000 with a total annual aggregate of \$3,000,000 with no deductible for claims made. The Hospital also had excess coverage of up to \$10,000,000 for individual claims and in the aggregate.

Effective March 1, 2005, the Hospital became a shareholder of the newly formed Freestate Healthcare Insurance Company, Ltd. (Freestate), a captive insurance company formed in the Cayman Islands. The Hospital maintains a 20% shareholder interest in Freestate. The Hospital decided to become a shareholder of Freestate when the Hospital's insurance company elected not to continue to write insurance policies for hospitals within the State of Maryland effective March 1, 2005. The Hospital believes that becoming a shareholder of a captive insurance company provides the best long-term solution to providing insurance coverage that is cost effective and predictable. Freestate provides insurance coverage on a claims-made basis to its owners and their affiliates for professional liability claims and comprehensive general liability of \$1,000,000 for each and every claim. Freestate has entered into reinsurance and excess policy agreements with independent insurance companies to limit its losses for professional liability and comprehensive general liability claims. The Hospital has \$10,000,000 of additional insurance in the aggregate through such reinsurance arrangements. Retrospective premium assessments and credits are calculated based on the aggregate experience of all named insureds under the policy. Each named insured's assessment or credit is based on the percentage of their actual exposure to the actual exposure of all named insureds. Each named insured will not be charged or entitled to any retrospective premium assessments or credits until the policy period has been closed and no further claim obligations are expected. In management's opinion, the assets of Freestate are sufficient to meet its obligations as of June 30, 2020. If the financial condition of Freestate were to materially deteriorate in the future, and Freestate was unable to pay its claim obligations, the responsibility to pay those claims would return to the member hospitals.

The Hospital is involved in litigation arising in the ordinary course of business. Claims alleging malpractice have been asserted against the Hospital and are currently in various stages of litigation. Additional claims may be asserted against the Hospital arising from services provided through June 30, 2020. The ultimate outcome of these matters cannot be determined at this time.

As of June 30, 2020 and 2019, the System recorded insurance recoverables and related professional claims liability of \$5,352,219 and \$4,339,175, respectively, in long-term assets and liabilities, respectively, in the accompanying consolidated statements of financial position. An estimated liability for incurred but not reported professional liability claims has also been recorded in the amount of approximately \$989,909 and \$641,549 in long-term liabilities as of June 30, 2020 and 2019, respectively. Management believes this estimate is adequate to provide for all professional liability claims that have been incurred through June 30, 2020 but not reported to its insurance carriers.

12. Maryland Health Services Cost Review Commission

Patient service revenue is recorded at rates established by the HSCRC. Effective July 1, 2016, the Hospital entered into a Global Budget Revenue (GBR) agreement with the HSCRC. The GBR agreement will renew each year for a one-year period unless it is cancelled by the HSCRC or by the Hospital. The GBR agreement provides the Hospital with a fixed revenue amount (CAP) under which it must operate each year. The CAP is adjusted annually for inflation, change in the Hospital's payor mix and uncompensated care, change in population and quality incentives. The Corporation's policy is to accrue revenue based on actual charges for services to patients in the year in which the services are performed and billed. For 2020, hospitals that are in an undercharge position due to the current pandemic (see Note 20) may not be able to recoup more than their undercharge net of any

applicable CARES Act funding (see Note 20). Approximately 97% of the total operating revenue of the Hospital is subject to the GBR model.

13. Concentration of Credit and Business Risk

The System provides health care services to residents located primarily in Calvert, St. Mary's, southern Anne Arundel and Charles counties. The System grants credit without collateral to its patients, most of whom are insured under third-party payor agreements, primarily with Medicare, Medicaid, and various commercial insurance companies. The System records accounts receivable net of estimated price concessions in 2020 and allowance for bad debts in 2019, and such amounts have historically been within management's expectations.

The mix of accounts receivable at June 30, 2020 and 2019 from patients and third-party payors is as follows:

	<u>2020</u>	2019
Medicare	33.6%	27.1%
Medicaid (including managed care)	12.6%	11.3%
Blue Cross	9.5%	11.8%
Commercial and other	6.7%	6.7%
Managed care	14.3%	15.2%
Self-pay	<u>23.3%</u>	27.9%
	<u> 100.0%</u>	100.0%

14. Functional Expenses

The System provides general health care services and related services to individual within its geographic location. Expenses related to providing these services, based on management's estimates of expense allocations, are as follows for the years ended June 30:

	2020			
	Healthcare Services	General and Administrative	<u>Fundraising</u>	Total
Salaries and wages	\$ 57,905,571	\$ 10,248,693	\$ 360,370	\$ 68,514,634
Employee benefits	10,298,426	1,837,508	65,564	12,201,498
Supplies	27,748,206	252,681	829	28,001,716
Purchased services	4,921,961	1,968,059	126,181	7,016,201
Professional fees	8,186,497	-		8,186,497
Depreciation and amortization	10,889,780	1,137,265	-	12,027,045
Interest	2,122,921	181,596	-	2,304,517
Other	<u>13,458,116</u>	5,378,504	(59,523)	18,777,098
Total	<u>\$135,531,478</u>	<u>\$ 21,004,307</u>	<u>\$ 493,421</u>	<u>\$157,029,206</u>

		201	9		
	Healthcare Services	General and Administrative		ndraising	Total
Salaries and wages	\$ 58,421,870	\$ 10,305,080	\$	360,999	\$ 69,087,949
Employee benefits	11,915,775	2,169,939		79,259	14,164,973
Supplies	28,617,772	146,477		2,898	28,767,147
Purchased services	4,620,588	2,035,276		149,515	6,805,379
Professional fees	7,924,056	· · ·		· -	7,924,056
Depreciation and amortization	10,528,322	1,133,620		_	11,661,942
Interest	1,712,288	146,470		-	1,858,758
Other	12,503,522	5,652,400		356,704	18,512,626
Total	<u>\$136,244,193</u>	<u>\$ 21,589,262</u>	\$	949,375	\$158,782,830

The accompanying consolidated financial statements report certain expense categories that are attributable to more than one health care service or support function. Therefore, these expenses require an allocation on a reasonable basis that is consistently applied. Costs not directly attributable to a function, including depreciation and amortization, interest, and other occupancy costs are allocated to a function based on a square footage basis.

15. Liquidity and Availability

As of June 30, 2020 and 2019, the System has working capital of approximately \$25,406,000 and \$21,182,000, respectively, and 308 and 296 average days, respectively, (based on normal expenditures) cash and investments without donor restriction on hand.

Financial assets available for general expenditure within one year of the balance sheet date consist of the following at June 30:

	2020	2019
Cash and cash equivalents	\$ 27,706,649	\$ 23,343,813
Accounts receivable, net	13,553,225	13,695,126
Other receivables	1,244,835	1,259,443
Assets whose use is limited	999,928	994,928
Total	<u>\$ 43,504,637</u>	\$ 39,293,310

In addition to the assets in the table above, the System has other investments and assets whose use is limited for specified purposes, and because they are not available for general expenditure within one year are not reflected in the amounts above. The System does, however, have investments and certain other long-term assets whose use is limited by board designation that could be made available for general expenditure within one year, if necessary.

16. Lease Obligations

The System is obligated under various operating leases for several office facilities and equipment. Total office rent and equipment lease expense was \$3,174,152 and \$3,490,569 for the years ended June 30, 2020 and 2019, respectively, and is reported as a component of other expenses in the accompanying consolidated statements of operations and other changes in net assets without donor restrictions.

The future minimum lease payments expected to be made to non-affiliated parties under non-cancelable operating leases are as follows for the years ending June 30:

2021	\$	3,098,631
2022		2,967,481
2023		2,523,248
2024		910,219
2025		354,814
	\$	9,854,393

Three of the four medical office buildings previously owned by the System were sold on August 29, 2013. As part of the sales transaction, the System continues to lease space in the buildings from the current owners. Rents to be received in the future from affiliated enterprises and other tenants are as follows for the years ending June 30:

2021	\$	648,607
2022		518,965
2023		301,900
2024		172,305
2025	_	<u>55,175</u>
	\$	1,696,952

Rental income totaling \$466,104 and \$360,247 has been recognized in the accompanying consolidated statements of operations and other changes in net assets without donor restrictions for the years ended June 30, 2020 and 2019, respectively.

17. Capital Leases

The Hospital is the lessee of equipment under a two capital leases, one expired in February 2020 and the second expiring in July 2022. The assets and liabilities under the capital leases are recorded at the lower of the present value of the minimum lease payments or the fair value of the asset. The assets are amortized over their estimated productive lives. Amortization of assets under the capital leases is included in depreciation expense for the year ended June 30, 2020.

Following is a summary of property held under the capital leases as of June 30, 2020:

	2020	2019
Information services equipment Accumulated amortization	\$ 4,261,56 (2,453,47	, , , , -
	<u>\$ 1,808,08</u>	<u>\$ 2,638,886</u>

Minimum future lease payments under the two capital leases are as follows for the years ending June 30:

		<u>Principal</u>		Interest	
2021 2022 2023	\$	757,053 798,183 68,441	\$	67,869 26,738 302	
	<u>\$</u>	1,623,677	\$	94,909	

18. Certain Risks and Uncertainties

The Hospital's ability to maintain or increase future revenue could be adversely affected by: (1) proposed or future changes in the laws, rules, regulations, and policies relating to the definition, activities, or taxation of not-for-profit tax-exempt entities; (2) the enactment into law of all or any part of the current budget resolutions under consideration by Congress related to Medicare and Medicaid reimbursement methodology or further reductions in payments to hospitals and other health care providers; (3) limited supply of physicians nationally which may limit the Hospital's ability to meet the healthcare demands of the population within its primary and secondary service areas; and (4) the ultimate impact of any changes to the federal Patient Protection and Affordable Care Act and the Health Care Education Affordability Reconciliation Act of 2010.

The Joint Commission, a non-governmental privately-owned entity, provides accreditation status to hospitals and other health care organizations in the United States. Such accreditation is based upon a number of requirements such as undergoing periodic surveys conducted by Joint Commission personnel. Certain managed care payors require hospitals to have appropriate Joint Commission accreditation in order to participate in those programs. In addition, the Center for Medicare and Medicaid Services (CMS), the agency with oversight of the Medicare and Medicaid programs, provides "deemed status" for facilities having Joint Commission accreditation. By being Joint Commission accredited, facilities are "deemed" to be in compliance with the Medicare and Medicaid conditions of participation. Termination as a Medicare provider or exclusion from any or all of these programs or payors would have a materially negative impact on the future financial position, operating results and cash flows of the Hospital. In September 2017, the Hospital was surveyed by the Joint Commission and received a full three-year Joint Commission accreditation through November 2020.

The HSCRC has jurisdiction over hospital reimbursement in Maryland by an agreement with the Centers for Medicare and Medicaid Services (CMS) based on a waiver from the Medicare prospective payment system under Section 1814(b) of the Social Security Act. In January 2014, CMS approved a waiver to modernize Maryland's unique all-payor rate-setting system for hospital services. The waiver consists of a five-year performance period. Maryland Hospitals committed to achieving significant quality improvements including reductions in 30-day readmissions and hospital acquired conditions. Maryland also limited annual Medicare per capita hospital cost growth to a rate lower than the national annual per capita growth rate per year for 2015 to 2018. Under this model, Medicare savings were estimated to be at least \$330 million. Under the waiver, Maryland shifted virtually all of its hospital revenue over the five-year performance period into global payment models.

In connection with the waiver, the HSCRC introduced new revenue arrangements, including the GBR model. This new model for Maryland hospitals moved payment to hospitals from each individual service to a total revenue for each hospital or a combination of hospitals to provide hospitals flexibility in the objectives of better care for individuals, higher levels of overall population health, and improved health care affordability. It removed the financial incentive from increasing volume and provided incentive to work with partners to provide care in the appropriate setting. Beginning January 2019, the new "Total Cost of Care Model" (the "Model") was approved and builds upon the successes of the all-payor model. The Model encourages continued clinical redesign and provides tools to providers to treat complex and chronic conditions and is built on the same global budget arrangement mechanics for revenue setting as the predecessor model. This is approved for a 10-year term provided Maryland meets the Model performance requirements.

The Medicare and state Medicaid reimbursement programs represent a substantial portion of the System's revenue and the System's operations are subject to a variety of other federal, state and local regulatory requirements. Failure to maintain required regulatory approvals and licenses and/or changes in such regulatory requirements could have a significant adverse effect on the System.

Changes in Federal and state reimbursement funding mechanisms and related government budgetary constraints could have a significant adverse effect on the System. The healthcare industry is subject to numerous laws and regulation from federal, state and local governments, and the government has increased enforcement of Medicare and Medicaid anti-fraud and abuse laws, as well as physician self-referral laws (STARK law and regulation). The System's compliance with these laws and regulations is subject to ongoing internal monitoring as well as periodic governmental review and inquiries, and the System has responded appropriately to any such compliance matters. The System is aware of certain asserted and unasserted compliance matters, and from time to time, the System

may agree to resolve certain compliance matters with the government through the self-disclosure process. The amount of such settlement for compliance matters currently being evaluated for submission under the self-disclosure process cannot be estimated at this time. The System will continue to monitor its compliance and all related government inquiries and respond appropriately, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medicaid programs. As result there is at least a reasonable possibility that the recorded estimates will change by a material amount in the near term.

As a result of pending federal healthcare reform legislation, substantial changes may occur in the healthcare system. Such legislation potentially includes numerous provisions affecting the delivery of healthcare services, the financing of healthcare costs, reimbursement to healthcare providers and the legal obligations of health insurers, providers and employers.

19. Endowment

Current accounting standards provide guidance on the net asset classification of donor-restricted endowment funds for a not-for-profit organization that is subject to an enacted version of the Uniform Prudent Management of Institutional Funds Act of 2006 (UPMIFA) and additional disclosures about an organization's endowment funds. The State of Maryland has adopted UPMIFA.

The System's endowment consists of two donor-restricted funds. Net assets associated with the endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

The Board of Directors of the System has interpreted the Maryland State Prudent Management of Institutional Funds Act (SPMIFA) as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the Hospital classifies as permanently restricted net assets, (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

In accordance with SPMIFA, the System considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- 1. The duration and preservation of the fund
- 2. The purposes of the System and the donor-restricted endowment fund
- 3. General economic conditions
- 4. The possible effect of inflation and deflation
- 5. The expected total return from income and the appreciation of investments
- 6. Other resources of the System
- 7. The investment policies of the System

From time to time, the fair value of assets associated with the endowment fund may decline below the level that the donor or SPMIFA required the System to retain as a fund of perpetual duration. There were no such deficiencies as of June 30, 2020 and 2019.

The System has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding while seeking to maintain the purchasing power of the endowment assets. Endowment assets include those assets of donor-restricted funds that the organization must hold in perpetuity. Under this policy, as approved by the Board of Directors, the endowment assets are invested in a manner that is intended to produce results that exceed the price and yield results of the Lehman Intermediate Government/Corporate Bond index while assuming a moderate level of investment risk. The System expects its endowment funds, over time, to provide an average rate of return of approximately 8% percent annually. Actual returns in any given year may vary from this amount.

To satisfy its long-term rate-of-return objectives, the System relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The System targets a diversified asset allocation that places a greater emphasis on highly liquid investments such as money market accounts to achieve its long-term return objectives within prudent risk constraints.

The endowment's net asset composition as of June 30, 2020 and 2019 a	nd the c	hanges therei	n, are a	as follows:
		ith Donor estriction		
Donor-restricted endowment, June 30, 2020	<u>\$</u>	1,115,844		
Changes in endowment net assets for the fiscal year June 30, 2020:				
		Without Donor estriction		/ith Donor lestriction
Endowment net assets, beginning of year	\$	-	\$	1,130,674
Investment return: Net appreciation (realized and unrealized)		-		33,170
Other changes: Contributions Released from restriction Used for designated purposes		- 48,000 (48,000)	_	(48,000)
Endowment net assets, end of year	<u>\$</u>		<u>\$</u>	1,115,844
		ith Donor estriction		
Donor-restricted endowment, June 30, 2019	\$	1,130,674		
Changes in endowment net assets for the fiscal year June 30, 2019:				
		Without Donor estriction		/ith Donor lestriction
Endowment net assets, beginning of year	\$	-	\$	1,130,612
Investment return: Net appreciation (realized and unrealized)		-		63,362
Other changes: Contributions Released from restriction Used for designated purposes		63,350 (63,350)		50 (63,350)
Endowment net assets, end of year	\$	-	\$	1,130,674

20. COVID-19 Pandemic

In response to the COVID-19 pandemic across the United States, the federal government and a large number of state governments, including Maryland, have imposed strict measures to curtail aspects of public life in an effort to control further spreading of COVID-19, including limitations on public gatherings, wearing of masks in public, and restrictions on restaurant and other businesses operating capacity.

An outbreak of an infectious disease, including the growth in the magnitude or severity of COVID-19 cases in the System's service area, could result in an abnormally high demand for health care services, potentially inundating hospitals with patients in need of intensive care services. The treatment of this highly contagious disease could also result in a temporary shutdown of areas of the facility or diversion of patients or staffing shortages. Additionally, elective services were being deferred in the later part of FY 2020, which resulted in in reduced patient volumes and operating revenues. Further, the changing global economic conditions or potential global health concerns surrounding the COVID-19 pandemic may also affect the System's partners, suppliers, distributors and payors, potentially disrupting or delaying the System's supply chain and delaying reimbursement by governmental, commercial or private payors, as well as impacting their creditworthiness and ability to pay. At this time, it is not possible to accurately predict the significance of the duration of the COVID-19 pandemic, the impact on operating income, the costs associated with responding to this pandemic, or what federal funds may continue be made available to help recover from this crisis. The System has implemented various cost saving measures to help mitigate any financial impact, including closing elective procedures, redeploying staff to high impact areas, setting up screening centers, establishing a decontamination process for N95 masks, and soliciting the community for handmade masks and PP&E.

In addition to the direct impact to the health care industry, global investment and financial markets have experienced substantial volatility, with significant declines attributed to COVID-19 concerns and associated economic impacts of the curtailment of public life described above. As with nearly all industries and companies operating through the COVID-19 pandemic, the System expects to encounter further volatility and disruption in its operations and in the local, national and global economies.

Although the System has activated plans to address the COVID-19 threat and is operating pursuant to infectious disease protocols and its emergency preparedness plan, the potential impact of the COVID-19 pandemic is difficult to predict and could materially adversely impact the System's financial condition, liquidity and results of operations in the future.

On March 27, 2020, the federal CARES Act was signed into law, which is intended to provide economic relief and emergency assistance for individuals, families and businesses affected by COVID-19. Various state governments are also taking action to provide economic relief and emergency assistance. The System received CARES Act Provider Relief Funds general and targeted distributions of \$3,954,469 and \$374,615 for the Hospital and CHMG, respectively during the year ended June 30, 2020. The System has recognized other operating revenue of \$3,954,469 and \$374,615 for the Hospital and CHMG, respectively related to this funding for the year ended June 30, 2020, to the extent the conditions for entitlement to such funding for healthcare related expenses or lost revenues to prevent, prepare for or respond to COVID-19, have been met for resulting in the simultaneous release of restrictions. Subsequent to June 30, 2020, the System received additional funding of \$3,900,000. The System has until June 30, 2021 to utilize remaining funds toward expenses attributable to COVID-19 but not reimbursed by other sources or to lost revenues per the terms and conditions.

Subsequent to June 30, 2020, on September 19, 2020, HHS issued a Post-Payment Notice of Reporting Requirements (PPNRR) which established the reporting criteria for providers which received Provider Relief Fund (PRF) funding under the CARES Act. The PPNRR also provided guidance related to the determination of lost revenues and COVID-19 related expenses under the terms and conditions of the PRF funding received by the System. Due to the nature and extent of the guidance that existed as of June 30, 2020, the issuance of the PPNRR is a substantial change from the initial guidance that the System operated under when attesting to the terms and conditions of the awards and the subsequent guidance HHS had previously issued through its "Frequently Asked Questions" on the PRF website through June 30, 2020. The guidance provided in the PPNRR is advisory in nature, and subject to change, and it is unknown at the report date what impacts this and future guidance will have on PRF funding and revenue recognition. Management has determined that the issuance of

Calvert Health System, Inc. and Subsidiaries Notes to Consolidated Financial Statements

this PPNRR guidance is a non-recognized subsequent event that does not provide additional information about the facts and circumstances that existed as of June 30, 2020. As a non-recognized subsequent event, the System has not changed its methodology for recognizing revenue during the year ended June 30, 2020, which was based on the guidance that was available and in effect as of year-end. As such, amounts recognized as other operating income for the year ended June 30, 2020 are subject to change and those changes could be material. The funds are also subject to future audits and potential adjustment and certain amounts may need to be repaid to the government.

Additionally, the System has elected payroll taxed deferrals of \$913,148 and \$129,488 for the Hospital and CHMG respectively, which are due back to the IRS in fiscal years 2021 and 2022, which are included in accounts payable and accrued expenses in the accompanying consolidated statement of financial position.



Current pascets		CalvertHealth Medical Center	CalvertHealth Foundation	Consolidating and Eliminating Entries	Consolidated CalvertHealth Medical Center
Shart cash equivalents \$12,835,722 \$138,171 \$ - \$12,973,893 \$136,174 \$ - \$12,903,943 \$14,903,943 \$1,903,94	ASSETS				
Short-term investments	Current assets:				
Patient accounts receivable, net 12,903,943 12,903,943 12,903,943 12,903,943 2,913,896 5,172,970 5,172,9	Cash and cash equivalents	\$ 12,835,722	\$ 138,171	\$ -	\$ 12,973,893
Investments 2,913,896 - 2,913,896 Prepaid expenses and other assets 5,172,970 - 5,172,970 999,928 Prepaid expenses and other assets 5,172,970 - - 999,928 Prepaid expenses and other assets 35,190,743 138,171 - 35,328,914 Prepaid expenses and other assets 35,190,743 138,171 - 35,328,914 Prepaid expenses 35,190,743 138,171 - 35,328,914 Prepaid expenses 1,307,469 825 - 1,308,294 Investments in wholly owned subsidiaries 5,994,468 - (5,994,468) (2) - (2) (2) (2) (2) (2) (2) (2) (2) (2) (3) (3) (3) (4)			-	-	
Prepaid expenses and other assets 5,172,970 - - 5,172,970 999,928 - - 999,928 - 999,928 - 999,928 999,928 - 999,928 999,928 999,928 999,928		·	-	-	·
Total current assets 35,190,743 138,171 - 35,328,914			-	-	
Total current assets	·		-	-	
Investments 1,307,469 825 - 1,308,294	Assets limited as of use, current	999,928			999,928
Investments in wholly owned subsidiaries 5,994,468 - (5,994,468) (2) - (2)	Total current assets	35,190,743	138,171		35,328,914
Investments in wholly owned subsidiaries 5,994,468 - (5,994,468) (2) - (2)	Investments	1,307,469	825	_	1,308,294
Assets limited as of use	Investments in wholly owned subsidiaries		-	(5,994,468) (2)	
Property and equipment, net 90,932,077 5,352,219	Investments in affiliated enterprises	4,360,568	-	-	4,360,568
Insurance recoverable 5,352,219 - - 5,352,219 753,740 - - 753,740 753,740		229,972	6,085,825	-	
Other assets 753,740 - - 753,740 Total assets \$ 144,121,256 \$ 6,224,821 \$ (5,994,468) \$ 144,351,609 LIABILITIES AND NET ASSETS Current liabilities: 8 8 727 \$ - \$ 18,009,278 Accounts payable and accrued expenses Intercompany accounts (229,626) 229,626 - - - Current portion of long-term debt 2,488,777 - - 2,488,777 - 2,488,777 - 2,248,777 - 2,488,777 - - 2,488,777 - - 2,488,777 - - 2,488,777 - - 2,488,777 - - 2,488,777 - - 2,396,279 - - 2,396,279 - - 2,396,279 - - 2,396,279 - - 24,191,387 - - 24,191,387 - - - 3,822,197 - - - 53,822,197 - - - 6,342,128 - <t< td=""><td></td><td></td><td>-</td><td>-</td><td></td></t<>			-	-	
Total assets \$144,121,256 \$6,224,821 \$(5,994,468) \$144,351,609			-	-	
LIABILITIES AND NET ASSETS Current liabilities: Accounts payable and accrued expenses Intercompany accounts \$ 18,008,551 \$ 727 \$ - \$ 18,009,278 Intercompany accounts (229,626) 229,626 - - - Current portion of long-term debt 2,488,777 - - 2,488,777 Current portion of capital lease obligation 757,053 - - 757,053 Advances from third-party payors 2,936,279 - - 2,936,279 Total current liabilities 23,961,034 230,353 - 24,191,387 Long-term debt, net 53,822,197 - - 53,822,197 Long-term debt, net 53,822,197 - - 53,822,197 Long-term capital lease obligation 866,624 - - 66,624 Professional liability 6,342,128 - - 6,342,128 Other long-term liabilities 1,307,469 - - 1,307,469 Total liabilities 86,299,452 230,353 - 86,529,805	Other assets	753,740			753,740
Current liabilities: Accounts payable and accrued expenses 18,008,551 \$ 727 \$ - \$ 18,009,278 Intercompany accounts (229,626) 229,626 Current portion of long-term debt 2,488,777 2,488,777 Current portion of capital lease obligation 757,053 757,053 Advances from third-party payors 2,936,279 2,936,279 Total current liabilities 23,961,034 230,353 - 24,191,387 Long-term debt, net 53,822,197 53,822,197 Long-term capital lease obligation 866,624 866,624 Professional liability 6,342,128 6,342,128 Other long-term liabilities 1,307,469 1,307,469 Total liabilities 86,299,452 230,353 - 86,529,805 Net assets: Without donor restrictions: Unrestricted - general 50,801,710 116,371 (116,371) (2) 50,801,710 (2) Unrestricted - board designated 4,029,583 3,029,583 (3,029,583) (2) 4,029,583 (2) With donor restrictions 2,990,511 2,848,514 (2,848,514) (2) 2,990,511 (2) Total net assets 57,821,804 5,994,468 (5,994,468) 57,821,804	Total assets	\$ 144,121,256	\$ 6,224,821	\$ (5,994,468)	\$ 144,351,609
Accounts payable and accrued expenses Intercompany accounts (229,626) 229,626	LIABILITIES AND NET ASSETS				
Intercompany accounts					
Current portion of long-term debt 2,488,777 - - 2,488,777 Current portion of capital lease obligation 757,053 - - 757,053 Advances from third-party payors 2,936,279 - - 2,936,279 Total current liabilities 23,961,034 230,353 - 24,191,387 Long-term debt, net 53,822,197 - - 53,822,197 Long-term capital lease obligation 866,624 - - 866,624 Professional liability 6,342,128 - - 6,342,128 Other long-term liabilities 1,307,469 - - 1,307,469 Total liabilities 86,299,452 230,353 - 86,529,805 Net assets: Without donor restrictions: Unrestricted - general 50,801,710 116,371 (116,371) (2) 50,801,710 (2) Unrestricted - board designated 4,029,583 3,029,583 (3,029,583) (2) 4,029,583 (2) With donor restrictions 2,990,511 2,848,514 (2,848,514) (2) 2,990,511 (2) 2,990,511 (2)			•	\$ -	\$ 18,009,278
Current portion of capital lease obligation 757,053 - - 757,053 Advances from third-party payors 2,936,279 - - 2,936,279 Total current liabilities 23,961,034 230,353 - 24,191,387 Long-term debt, net 53,822,197 - - 53,822,197 Long-term capital lease obligation 866,624 - - 866,624 Professional liability 6,342,128 - - 6,342,128 Other long-term liabilities 1,307,469 - - 1,307,469 Total liabilities 86,299,452 230,353 - 86,529,805 Net assets: Without donor restrictions: Unrestricted - general 50,801,710 116,371 (116,371) (2) 50,801,710 (2) Unrestricted - board designated 4,029,583 3,029,583 (3,029,583) (2) 4,029,583 (2) With donor restrictions 2,990,511 2,848,514 (2,848,514) (2) 2,990,511 (2) Total net assets 57,821,804 5,994,468 (5,994,468) 57,821,804 <td>·</td> <td></td> <td>229,626</td> <td>-</td> <td>-</td>	·		229,626	-	-
Advances from third-party payors 2,936,279 - - 2,936,279 Total current liabilities 23,961,034 230,353 - 24,191,387 Long-term debt, net 53,822,197 - - - 53,822,197 Long-term capital lease obligation 866,624 - - - 866,624 Professional liability 6,342,128 - - - 6,342,128 Other long-term liabilities 1,307,469 - - 1,307,469 Total liabilities 86,299,452 230,353 - 86,529,805 Net assets: Without donor restrictions: Unrestricted - general 50,801,710 116,371 (116,371) (2) 50,801,710 (2) Unrestricted - board designated 4,029,583 3,029,583 (3,029,583) (2) 4,029,583 (2) With donor restrictions 2,990,511 2,848,514 (2,848,514) (2) 2,990,511 (2) Total net assets 57,821,804 5,994,468 (5,994,468) 57,821,804			-	-	
Total current liabilities 23,961,034 230,353 - 24,191,387 Long-term debt, net 53,822,197 - - 53,822,197 Long-term capital lease obligation 866,624 - - 866,624 Professional liability 6,342,128 - - 6,342,128 Other long-term liabilities 1,307,469 - - 1,307,469 Total liabilities 86,299,452 230,353 - 86,529,805 Net assets: Without donor restrictions: Unrestricted - general 50,801,710 116,371 (116,371) (2) 50,801,710 (2) Unrestricted - board designated 4,029,583 3,029,583 (3,029,583) (2) 4,029,583 (2) With donor restrictions 2,990,511 2,848,514 (2,848,514) (2) 2,990,511 (2) Total net assets 57,821,804 5,994,468 (5,994,468) 57,821,804			-	-	
Long-term debt, net 53,822,197 53,822,197 Long-term capital lease obligation 866,624 866,624 Professional liability 6,342,128 6,342,128 Other long-term liabilities 1,307,469 1,307,469 Total liabilities 86,299,452 230,353 - 86,529,805 Net assets: Without donor restrictions: Unrestricted - general 50,801,710 116,371 (116,371) (2) 50,801,710 (2) Unrestricted - board designated 4,029,583 3,029,583 (3,029,583) (2) 4,029,583 (2) With donor restrictions 2,990,511 2,848,514 (2,848,514) (2) 2,990,511 (2) Total net assets 57,821,804 5,994,468 (5,994,468) 57,821,804	Advances from third-party payors	2,936,279			2,930,279
Long-term capital lease obligation 866,624 - - 866,624 Professional liability 6,342,128 - - 6,342,128 Other long-term liabilities 1,307,469 - - 1,307,469 Total liabilities 86,299,452 230,353 - 86,529,805 Net assets: Without donor restrictions: Unrestricted - general 50,801,710 116,371 (116,371) (2) 50,801,710 (2) Unrestricted - board designated 4,029,583 3,029,583 (3,029,583) (2) 4,029,583 (2) With donor restrictions 2,990,511 2,848,514 (2,848,514) (2) 2,990,511 (2) Total net assets 57,821,804 5,994,468 (5,994,468) 57,821,804	Total current liabilities	23,961,034	230,353	<u> </u>	24,191,387
Long-term capital lease obligation 866,624 - - 866,624 Professional liability 6,342,128 - - 6,342,128 Other long-term liabilities 1,307,469 - - 1,307,469 Total liabilities 86,299,452 230,353 - 86,529,805 Net assets: Without donor restrictions: Unrestricted - general 50,801,710 116,371 (116,371) (2) 50,801,710 (2) Unrestricted - board designated 4,029,583 3,029,583 (3,029,583) (2) 4,029,583 (2) With donor restrictions 2,990,511 2,848,514 (2,848,514) (2) 2,990,511 (2) Total net assets 57,821,804 5,994,468 (5,994,468) 57,821,804	Long-term debt, net	53,822,197	-	-	53,822,197
Other long-term liabilities 1,307,469 - - 1,307,469 Total liabilities 86,299,452 230,353 - 86,529,805 Net assets: Without donor restrictions: Unrestricted - general 50,801,710 116,371 (116,371) (2) 50,801,710 (2) Unrestricted - board designated 4,029,583 3,029,583 (3,029,583) (2) 4,029,583 (2) With donor restrictions 2,990,511 2,848,514 (2,848,514) (2) 2,990,511 (2) Total net assets 57,821,804 5,994,468 (5,994,468) 57,821,804			-	-	
Total liabilities 86,299,452 230,353 - 86,529,805 Net assets: Without donor restrictions: Unrestricted - general 50,801,710 116,371 (116,371) (2) 50,801,710 (2) Unrestricted - board designated 4,029,583 3,029,583 (3,029,583) (2) 4,029,583 (2) With donor restrictions 2,990,511 2,848,514 (2,848,514) (2) 2,990,511 (2) Total net assets 57,821,804 5,994,468 (5,994,468) 57,821,804	Professional liability	6,342,128	-	-	6,342,128
Net assets: Without donor restrictions: Unrestricted - general 50,801,710 116,371 (116,371) (2) 50,801,710 (2) Unrestricted - board designated 4,029,583 3,029,583 (3,029,583) (2) 4,029,583 (2) With donor restrictions 2,990,511 2,848,514 (2,848,514) (2) 2,990,511 (2) Total net assets 57,821,804 5,994,468 (5,994,468) 57,821,804	Other long-term liabilities	1,307,469			1,307,469
Without donor restrictions: Unrestricted - general 50,801,710 116,371 (116,371) (2) 50,801,710 (2) Unrestricted - board designated 4,029,583 3,029,583 (3,029,583) (2) 4,029,583 (2) With donor restrictions 2,990,511 2,848,514 (2,848,514) (2) 2,990,511 (2) Total net assets 57,821,804 5,994,468 (5,994,468) 57,821,804	Total liabilities	86,299,452	230,353		86,529,805
Without donor restrictions: Unrestricted - general 50,801,710 116,371 (116,371) (2) 50,801,710 (2) Unrestricted - board designated 4,029,583 3,029,583 (3,029,583) (2) 4,029,583 (2) With donor restrictions 2,990,511 2,848,514 (2,848,514) (2) 2,990,511 (2) Total net assets 57,821,804 5,994,468 (5,994,468) 57,821,804	Not exects:				
Unrestricted - general 50,801,710 116,371 (116,371) (2) 50,801,710 (2) Unrestricted - board designated 4,029,583 3,029,583 (3,029,583) (2) 4,029,583 (2) With donor restrictions 2,990,511 2,848,514 (2,848,514) (2) 2,990,511 (2) Total net assets 57,821,804 5,994,468 (5,994,468) 57,821,804					
Unrestricted - board designated 4,029,583 3,029,583 (3,029,583) (2) 4,029,583 (2) With donor restrictions 2,990,511 2,848,514 (2,848,514) (2) 2,990,511 (2) Total net assets 57,821,804 5,994,468 (5,994,468) 57,821,804		50 801 710	116 371	(116 371) (2)	50 801 710 (2)
With donor restrictions 2,990,511 2,848,514 (2,848,514) (2) 2,990,511 (2) Total net assets 57,821,804 5,994,468 (5,994,468) 57,821,804					
					·
Total liabilities and net assets <u>\$ 144,121,256</u> <u>\$ 6,224,821</u> <u>\$ (5,994,468)</u> <u>\$ 144,351,609</u>	Total net assets	57,821,804	5,994,468	(5,994,468)	57,821,804
	Total liabilities and net assets	\$ 144,121,256	\$ 6,224,821	\$ (5,994,468)	\$ 144,351,609

	CalvertHealth Medical Center	CalvertHealth Foundation	Consolidating and Eliminating Entries	Consolidated CalvertHealth Medical Center
Revenue:				
Net patient service revenue	\$ 135,665,635	\$ -	\$ -	\$ 135,665,635
CARES Act provider relief funding	3,954,469	-	-	3,954,469
Other operating revenue	2,836,275	2,083,804	(2,052,965) (6)(7)	2,867,114
Total operating revenue	142,456,379	2,083,804	(2,052,965)	142,487,218
Expense:				
Salaries & wages	58,897,489	=	-	58,897,489
Employee benefits	10,715,564	=	-	10,715,564
Supplies	21,892,017	-	-	21,892,017
Purchased services	6,491,298	126,181	-	6,617,479
Professional fees	8,026,018	-	-	8,026,018
Depreciation and amortization	11,699,676	=	-	11,699,676
Interest	2,304,517	-	=	2,304,517
Other	17,369,631	1,994,271	(2,052,965) (6)(7)	17,310,937
Total operating expenses	137,396,210	2,120,452	(2,052,965)	137,463,697
Income (loss) from operations	5,060,169	(36,648)	-	5,023,521
Nonoperating gains:				
Investment income	83,289	106,714	=	190,003
Income from equity investments	469,952	, -	15,132 (4)	485,084
Net unrealized gains (losses) on investments (see Note 1 for				· <u>-</u>
details on the implementation of ASU 2016-01)		(3,441)	-	(3,441)
Total nonoperating gains (losses), net	553,241	103,273	15,132	671,646
Excess of revenue over expenses (expenses over revenue)	5,613,410	66,625	15,132	5,695,167
Transfer of net assets:				
Net assets released from restrictions for capital acquisitions	1,883,439	_	-	1,883,439
Transfer of net assets	(100,000)	(100,000)	100,000	(100,000)
Equity contributions	(9,111,001)	(.55,500)	-	(9,111,001)
. ,				
Increase in net assets without donor restrictions	\$ (1,714,152)	\$ (33,375)	\$ 115,132	\$ (1,632,395)

	Calvert Health Medical Center	Calvert Health Foundation	Consolidating and Eliminating Entries	Consolidated Calvert Memorial Hospital
Cash flows from operating activities:				
Increase (decrease) in net assets	\$ (2,891,142)	\$ (1,299,623)	\$ 1,299,623 (2) \$ (2,891,142)
Adjustments to reconcile to net cash from operating activities:	44 000 070			44 000 070
Depreciation and amortization	11,699,676	-	-	11,699,676
Amortization of debt issuance costs	61,744	(400.045)	-	61,744
Donations restricted for capital acquisition	45.400	(426,815)	(45.400) (4	(426,815)
Equity in earnings of wholly owned subsidiaries	15,132	-	(15,132) (4	
Equity in earnings of affiliated enterprises	(485,084)	-	-	(485,084)
Distributions from equity method investments	439,536	(40.040)	-	439,536
Realized net gains on investments	-	(10,948)	-	(10,948)
Unrealized net gains on investments	-	3,441	-	3,441
Change in: Patient accounts receivable	(550,225)			(550,225)
Inventories	(559,325)	-	-	(559,325)
	(569,037)	-	-	(569,037)
Prepaid expenses and other assets	(2,290,680)	(460.007)	-	(2,290,680)
Accounts payable, accrued expenses and other liabilities	11,386,750	(160,887)		11,225,863
Net cash provided by operating activities	16,807,570	(1,894,832)	1,284,491	16,197,229
Cash flows from investing activities:				
Purchases of investments	(302,214)	(825)	_	(303,039)
Proceeds from sales of investments	94,319	() -	_	94,319
Net increase in assets limited as to use	-	(248,874)	_	(248,874)
Distributions from equity method investments	1,650,894	(2:0,0::)	(1,284,491) (5	, ,
Purchases of property and equipment	(13,381,930)	_	(1,201,101)	(13,381,930)
, arenaded or property and equipment	(10,001,000)			(10,001,000)
Net cash used in investing activities	(11,938,931)	(249,699)	(1,284,491)	(13,473,121)
Cash flows from financing activities:				
Repayment of long-term debt	(2,489,693)	_	_	(2,489,693)
Payments on capital leases	(794,127)	_	_	(794,127)
Donations received restricted for capital acquisitions	-	426,815	-	426,815
		· · · · · ·		· · · · · · · · · · · · · · · · · · ·
Net cash (used in) provided by financing activities	(3,283,820)	426,815		(2,857,005)
Net change in cash, cash equivalents, and restricted cash	1,584,819	(1,717,716)	-	(132,897)
Cash, cash equivalents, and restricted cash beginning of year	12,480,803	3,141,838		15,622,641
Cash, cash equivalents and restricted cash, end of year	\$ 14,065,622	\$ 1,424,122	\$ -	\$ 15,489,744

	Consolidated CalvertHealth Medical Center	С	alvertHealth Medical Group	Calvert Health Ventures	CMH Holding Company	I	CMH II Holding Company	S	Calvert Health ystem, Inc.	Consolidating and Eliminating Entries			Consolidated Calvert Health System, Inc.	
ASSETS														
Current assets:														
Cash and cash equivalents	\$ 12,973,893	\$	1,981,950	\$ 3,311,351	\$ 63,981	\$	7,180	\$	9,368,294	\$	-	\$	27,706,649	
Short-term investments	364,284		-	-	-		-		-		-		364,284	
Patient accounts receivable, net	12,903,943		649,282	-	-		-		-		-		13,553,225	
Inventories	2,913,896		164,357	-	-		-		-		-		3,078,253	
Prepaid expenses and other assets	5,172,970		299,826	11,649	82,982		(2,111)		-		(74,067) (1)		5,491,249 ⁽¹⁾	
Assets limited as to use, current	999,928		-		 						<u> </u>		999,928	
Total current assets	35,328,914		3,095,415	3,323,000	146,963		5,069		9,368,294		(74,067)		51,193,588	
Investments	1,308,294		-	-	_		_		92,649,506		-		93,957,800	
Investments in wholly owned subsidiaries	-		-	-	_		-		7,506,678		(7,506,678) (2)(5)	_ (2)(5)	į
Investments in affiliated enterprises	4,360,568		-	2,403,497	_		-		225,000		-		6,989,065	
Assets limited as of use	6,315,797		-	-	_		-		-		-		6,315,797	
Property and equipment, net	90,932,077		270,998	-	1,103,159		528,392		-		-		92,834,626	
Insurance recoverable	5,352,219		-	-	_		-		-		-		5,352,219	
Other assets	753,740		65,000		 						<u>-</u>		818,740	
Total assets	\$ 144,351,609	\$	3,431,413	\$ 5,726,497	\$ 1,250,122	\$	533,461	\$ ^	109,749,478	\$	(7,580,745)	\$	257,461,835	

(Continued)

	Consolidated CalvertHealth Medical Center	CalvertHealth Medical Group	Calvert Health Ventures	CMH Holding Company	CMH II Holding Company	Calvert Health System, Inc.	Consolidating and Eliminating Entries	Consolidated Calvert Health System, Inc.
LIABILITIES AND NET ASSETS Current liabilities:								
Accounts payable and accrued expenses Current portion of long-term debt	\$ 18,009,278 2,488,777	\$ 1,346,215 -	\$ 305,017	\$ 19,089 -	\$ - -	\$ - -	\$ (74,067) ⁽¹⁾	\$ 19,605,532 ⁽¹⁾ 2,488,777
Current portion of capital lease obligation Advances from third-party payors	757,053 2,936,279						<u> </u>	757,053 2,936,279
Total current liabilities	24,191,387	1,346,215	305,017	19,089			(74,067)	25,787,641
Long-term debt, less current portion Long-term capital lease obligation	53,822,197 866,624	-	-	-	-	-	-	53,822,197 866,624
Professional liability	6,342,128	-	-	-	-	-	- -	6,342,128
Other long-term liabilities	1,307,469						<u> </u>	1,307,469
Total liabilities	86,529,805	1,346,215	305,017	19,089			(74,067)	88,126,059
Net assets: Without donor restrictions:								
Unrestricted - general	50,801,710	2,085,198	5,421,480	1,231,033	533,461	109,749,478	(7,506,678) (2)(5)	162,315,682 (2)(5)
Unrestricted - board designated	4,029,583	-	-	-	-	-	-	4,029,583
With donor restrictions	2,990,511					-	- _	2,990,511
Total net assets	57,821,804	2,085,198	5,421,480	1,231,033	533,461	109,749,478	(7,506,678)	169,335,776
Total liabilities and net assets	\$ 144,351,609	\$ 3,431,413	\$ 5,726,497	\$ 1,250,122	\$ 533,461	\$ 109,749,478	\$ (7,580,745)	\$ 257,461,835

	Consolidated CalvertHealth Medical Center	CalvertHealth Medical Group	Calvert Health Ventures	CMH Holding Company	CMH II Holding Company	Calvert Health System, Inc.	Consolidating and Eliminating Entries	Consolidated Calvert Health System, Inc.
Revenue:								
Net patient service revenue	\$ 135,665,635	\$ 14,700,978	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 150,366,613
Rental revenue		56,716	-	639,812	12,576	-	(243,000) (3)	466,104 (3)
CARES Act provider relief funding	3,954,469	374,615		-	-	-	-	4,329,084
Other operating revenue	2,867,114	323,919	5,190				(535,538) (3)	2,660,685 (3)
Total operating revenue	142,487,218	15,456,228	5,190	639,812	12,576	-	(778,538)	157,822,486
Expenses:								
Salaries & wages	58,897,489	9,617,145	-	-	-	-	-	68,514,634
Employee benefits	10,715,564	1,485,934	-	-	-	-	-	12,201,498
Supplies	21,892,017	6,046,334	-	-	-	-	63,365	28,001,716
Purchased services	6,617,479	586,567	6,366	235,327	-	-	(429,538) (3)	7,016,201 (3)
Professional fees	8,026,018	160,479	-	-	-	-	-	8,186,497
Depreciation and amortization	11,699,676	112,038	-	214,932	399	-	-	12,027,045
Interest	2,304,517	-	-	-	-	-	-	2,304,517
Other	17,310,937	1,696,885		181,896	(255)		(412,365) (3)	18,777,098 (3)
Total operating expenses	137,463,697	19,705,382	6,366	632,155	144		(778,538)	157,029,206
Income (loss) from operations	5,023,521	(4,249,154)	(1,176)	7,657	12,432	-	-	793,280
Nonoperating gains (losses):								
Investment income	190,003	-	876	-	-	2,947,651	-	3,138,530
Income (loss) from equity investments	485,084	-	903,914	-	-	(3,649,975)	3,649,975 (4)	1,388,998 (4)
Income tax expense	-	-	(304,000)	-	-	-	-	(304,000)
Net unrealized gains (losses) on investments (see Note 1 for details on								
the implementation of ASU 2016-01)	(3,441)	-	-	-	-	(974,158)	-	(977,599)
Total nonoperating gains (losses), net	671,646	-	600,790	-	-	(1,676,482)	3,649,975	3,245,929
Excess of revenue over expenses (expenses over revenue)	5,695,167	(4,249,154)	599,614	7,657	12,432	(1,676,482)	3,649,975	4,039,209
Net assets released from restrictions for capital acquisitions	1,883,439	_	_	_	_	_	_	1,883,439
Transfer of net assets	(100,000)	-	-	-	_	-	-	(100,000)
Equity contributions	(9,111,001)	12,582,751	(471,750)	(310,000)	(14,000)	9,435,001	(12,111,001) (5)	_ (5)
Contributions from noncontrolling interest holders						(37,067)	37,067	<u> </u>
Increase (decrease) in net assets without donor restrictions	\$ (1,632,395)	\$ 8,333,597	\$ 127,864	\$ (302,343)	\$ (1,568)	\$ 7,721,452	\$ (8,423,959)	\$ 5,822,648

	Consolidated CalvertHealth Medical Center	CalvertHealth Medical Group	Calvert Health Ventures	CMH Holding Company	CMH II Holding Company	Calvert Health System, Inc.	Consolidating and Eliminating Entries	Consolidated Calvert Health System, Inc.
Cash flows from operating activities:								
Increase (decrease) in net assets	\$ (2,891,142)	\$ 8,333,597	\$ 127,864	\$ (302,343)	\$ (1,568)	\$ 7,721,452	\$ (8,423,959) (2)	\$ 4,563,901 (2)
Adjustments to reconcile to net cash from operating activities:								
Depreciation and amortization	11,699,676	112,038	-	214,932	399	-	-	12,027,045
Amortization of debt issuance costs	61,744	-	-	-	-	-	-	61,744
Donations restricted for capital acquisition	(426,815)	-	-	-	-	-	-	(426,815)
Equity in earnings of wholly owned subsidiaries	-	-	-	-	-	3,649,975	(3,649,975) (4)	- (4)
Equity in earnings of affiliated enterprises	(485,084)	-	(903,914)	-	-	-	-	(1,388,998)
Distributions from equity method investments	439,536	-	520,313	-	-	508,817	(508,817) (5)	959,849
Realized net (gains) losses on investments	(10,948)	-	-	-	-	(597,312)	-	(608,260)
Unrealized net gains on investments	3,441	-	-	-	-	974,158	-	977,599
Change in:								
Patient accounts receivable	(559,325)	701,226	-	-	-	-	-	141,901
Inventories	(569,037)	23,528	-	-	-	-	-	(545,509)
Prepaid expenses and other assets	(2,290,680)	87,453	4,070	26,042	3,159	-	(95,530) (1)	(2,265,486) (1)
Accounts payable, accrued expenses and other liabilities	11,225,863	(7,786,588)	752,373	8,631	-	<u> </u>	95,530 (1)	4,295,809 (1)
Net cash provided by (used in) operating activities	16,197,229	1,471,254	500,706	(52,738)	1,990	12,257,090	(12,582,751)	17,792,780
Cash flows from investing activities:								
Purchases of investments	(303,039)	_	-	_	-	(40,726,506)	-	(41,029,545)
Proceeds from sales of investments	94,319	_	-	_	_	42,253,811	-	42,348,130
Net increase in assets limited as to use	(248,874)	_	-	_	-	-	-	(248,874)
Distributions from equity method investments	366,403	_	38,937	-	_	(12,807,751)	12,582,751 (5)	180,340 (5)
Purchases of property and equipment	(13,381,930)	(28,068)	· -	(9,510)	-	-	-	(13,419,508)
Net cash used in provided by investing activities	(13,473,121)	(28,068)	38,937	(9,510)		(11,280,446)	12,582,751	(12,169,457)
Net cash used in provided by investing activities	(13,473,121)	(20,000)	30,937	(9,510)		(11,200,440)	12,302,731	(12,109,457)
Cash flows from financing activities:								
Repayment of long-term debt	(2,489,693)	_	-	_	_	-	-	(2,489,693)
Payments on capital leases	(794,127)	_	-	_	_	-	-	(794,127)
Donations received restricted for capital acquisitions	426,815	_	-	_	_	-	-	426,815
' '								
Net cash (used in) provided by financing activities	(2,857,005)							(2,857,005)
Net change in cash, cash equivalents, and restricted cash	(132,897)	1,443,186	539,643	(62,248)	1,990	976,644	-	2,766,318
Cash, cash equivalents, and restricted cash, beginning of year	15,622,641	538,764	2,771,708	126,229	5,190	8,391,650		27,456,182
Cash, cash equivalents, and restricted cash, end of year	\$ 15,489,744	\$ 1,981,950	\$ 3,311,351	\$ 63,981	\$ 7,180	\$ 9,368,294	\$ -	\$ 30,222,500

Calvert Health System, Inc. and Subsidiaries Description of Consolidating and Eliminating Entries Year Ended June 30, 2020

- 1. To eliminate intercompany payables/receivables.
- 2. To eliminate investment in subsidiaries and related net asset accounts.
- 3. To eliminate intercompany income/expense generated from support and building service fees, staffing contracts and operating leases.
- 4. To eliminate income of wholly owned subsidiaries.
- 5. To eliminate intercompany transfer of equity and assets.
- 6. To eliminate revenue/expense for Calvert Memorial Hospital Foundation, Inc. for contributions transferred to the Hospital for the acquisition of property, plant and equipment.
- 7. To eliminate revenue/expense for Calvert Memorial Hospital Foundation, Inc. for contributions transferred to the Hospital to fund operating programs.